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ABSTRACT  
   
Host organisms have evolved multiple mechanisms to defend against a 
viral infection and likewise viruses have evolved multiple methods to subvert the 
host’s anti-viral immune response.  Vaccinia virus (VACV) is known to contain 
numerous proteins involved in blocking the cellular anti-viral immune response.  
The VACV E3L protein is important for inhibiting the anti-viral immune response 
and deletions within this gene lead to a severe attenuation.  In particular, VACV 
containing N-terminal truncations in E3L are attenuated in animal models and fail 
to replicate in murine JC cells.  Monkeypox virus (MPXV) F3L protein is a 
homologue of the VACV E3L protein, however it is predicted to contain a 37 
amino acid N-terminal truncation.  Despite containing an N-terminal truncation in 
the E3L homologue, MPXV is able to inhibit the anti-viral immune response 
similar to wild-type VACV and able to replicate in JC cells.  This suggests that 
MPXV has evolved another mechanism(s) to counteract host defenses and 
promote replication in JC cells.  MPXV produces less dsRNA than VACV during 
the course of an infection, which may explain why MPXV posses a phenotype 
similar to VACV, despite containing a truncated E3L homologue.  
The development of oncolytic viruses as a therapy for cancer has gained 
interest in recent years.  Oncolytic viruses selectively replicate in and destroy 
cancerous cells and leave normal cells unharmed.  Many tumors possess 
dysregulated anti-viral signaling pathways, since these pathways can also regulate 
cell growth.  Creating a mutation in the N-terminus of the VACV-E3L protein 
generates an oncolytic VACV that depends on dysregulated anti-viral signaling 
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pathways for replication allowing for direct targeting of the cancerous cells.  
VACV-E3L∆54N selectively replicates in numerous cancer cells lines and not in 
the normal cell lines.  Additionally, VACV-E3L∆54N is safe and effective in 
causing tumor regression in a xenograph mouse model.  Lastly, VACV-E3L∆54N 
was capable of spreading from the treated tumors to the untreated tumors in both a 
xenograph and syngeneic mouse model. These data suggest that VACV-
E3L∆54N could be an effective oncolytic virus for the treatment of cancer.  
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OVERALL INTRODUCTION 
All known organisms have evolved numerous ways to protect themselves 
from viral infections. It was necessary for these organisms to develop multiple 
mechanisms to detect and protect against a viral infection, given that viruses are 
on the most rapidly evolving pathogens that organism will ever encounter. Since 
viruses are obligate intracellular parasites that require the hosts’ cellular 
machinery to replicate, they simultaneously evolved multiple strategies to counter 
the mechanisms used by the host to protect against a viral infection. Viral 
infections of host cells leads to the initiation of an anti-viral innate immune 
response resulting in the induction of type I interferons (IFNs) and other pro-
inflammatory cytokines (18).  Ultimately, the induction of cellular IFN and 
cytokines results in the establishment of an anti-viral state; wherein most virus 
will no longer be able to replicate and spread to the surrounding uninfected cells.   
 Type I IFNs (IFNα/β) are the main cytokines involved in the innate anti-
viral response and are produced by all nucleated cells in response to a viral 
infection (72). The binding of type I IFNs to their cellular surface receptors 
triggers the activation of multiple signaling cascades inducing the transcription of 
numerous IFN-stimulated genes (ISGs) (42). These ISGs are responsible for 
establishing the anti-viral state in the cells by directly targeting cellular 
mechanisms required for viral replication, bolstering the host’s ability to detect 
viral infections and/or increasing IFN production to protect uninfected cells and 
limit virus spread (18). Furthermore, IFNα/βs are also known to affect portions of 
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the adaptive immune response through priming T helper and cytotoxic T cells 
(CTLs), thereby inducing an antigen specific response (98, 103, 128).   
 The production of IFN and the activation of ISGs are regulated through 
intracellular signaling pathways that are activated by the host’s pattern 
recognition receptors (PRRs). These receptors recognize a broad range of 
pathogen-associated molecular patterns (PAMPs) that are produced by 
microorganisms once they have infected a cell. In the case of viral infections, 
some of the most important PAMPs recognized by the PRRs are viral nucleic 
acids. Currently there are two known groups of PRRs that are responsible for 
recognizing viral nucleic acids. The first are a group of four toll-like receptors 
(TLRs), TLR3, TLR7, TLR8, and TLR9 (18). The second group of receptors are 
the retinoic-acid-inducible gene I (RIG-I)- like receptors (RLRs) that include 
RIG-I and melanoma differentiation-associated gene 5 (MDA-5) (18). These two 
families of receptors are the first line of defense in preventing against a viral 
infection and limiting the spread of the virus throughout the body.  
 The TLR family of proteins is composed of membrane bound proteins 
known to be present on the cell surface or within endosomes. In the case of TLR3, 
TLR7, TLR8, and TLR9, they are mainly found within endosomes (72). TLR7 
and TLR8 are known to be activated by single-stranded RNA (ssRNA), which is 
essential for detecting RNA viruses (17), while TLR 9 is known to recognize the 
unmethylated CpG DNA present within the genomes of DNA viruses (74, 77).  
TLR3 appears to be more specific towards detecting a viral infection, as it has 
been shown to be activated by double-stranded RNA (dsRNA), a byproduct of 
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viral replication and transcription for both RNA and DNA viruses, respectively 
(4). Upon activation, TLR7, TLR8, and TLR9 signal through the adapter protein 
myeloid differentiation primary response gene 88 (MyD88) leading to the 
activation of transcription factors including the IFN regulatory factor 7 (IRF-7), 
the nuclear factor κB (NF-κB), the activating protein 1 (AP-1), and the mitogen-
activated protein kinase pathways (MAPK). In contrast, TLR3 signals through the 
adapter protein TIR domain-containing adapter-inducing IFN-β (TRIF) (Fig. 1) 
(143). In addition to the transcription factors activated by TLR8 and TLR9, TLR3 
also activates another transcription factor, IRF-3. Ultimately these activated 
transcription factors promote the production of IFN-α/β and other inflammatory 
cytokines, thereby increasing the host’s ability to counter a viral infection.   
 The two most well characterized PAMP sensors within the RLR family of 
proteins are RIG-I and MDA-5.  These proteins are IFN inducible, cytoplasmic 
RNA helicases that appear to be the main sensors responsible for identifying 
PAMPs within the cytoplasm of infected cells (129). Similar to TLR3, RIG-I and 
MDA-5 appear to be specifically designed to recognize viral PAMPs, as RIG-I 
binds to 5’-triphosphorylated ssRNA (96) and short dsRNA (127), whereas 
MDA-5 preferentially recognizes longer forms of dsRNA (59).  RIG-I and MDA-
5 contain two amino-terminal (N-terminal) caspase recruitment domains (CARD) 
and a carboxy-terminal (C-terminal) DExD/H box RNA helicase domain.  The C-
terminal domain is responsible for recognizing viral dsRNA and leading to their 
activation (58). The CARD domains of activated RIG-I and MDA-5 interact with 
the downstream adapter protein IFN-β promoter stimulator 1 (IPS-1) also known 
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as mitochondrial anti-viral signaling protein (MAVS), virus-induced signaling 
adapter (VISA), and CARD adaptor-inducing IFN-β (CARDIF) (Fig. 1) (61, 85, 
111, 142). Activated IPS-1 associates with tumor necrosis factor receptor-
associated factor 3 (TRAF3) and activates TANK-binding kinase (TBK-1) and 
inhibitor of NF-κB kinase ε (IKKε) (81).  TBK-1 and IKKε phosphorylate and 
activate IRF-3, IRF-7, and NF-κB, which leads to an induction of IFN-α/β and 
other inflammatory cytokines (53, 126).  
 Type 1 IFNs are known to induce the expression of hundreds of ISGs (41) 
and several of these ISGs have been shown to be important for detecting PAMPs 
and contribute to the host’s immune response. Two ISGs that have been most 
widely studied and characterized are the dsRNA dependent protein kinase R 
(PKR) and 2’-5’ oligoadenylate synthetase (OAS). PKR belongs to a family of 
proteins that respond to environmental stresses and regulate cellular protein 
synthesis. It is constitutively expressed in all cells at a basal level, but following 
IFN treatment the levels of PKR can be highly upregulated (103). PKR is a 
serine/threonine kinase composed of two N-terminal dsRNA binding domains and 
a C-terminal kinase domain (84). Upon binding to dsRNA, PKR will dimerize and 
undergo an autophosphorylation event in the kinase domain leading to activation 
of the protein (104). One of the most widely characterized substrates for PKR is 
the α subunit of the eukaryotic translational initiation factor 2 (eIF2α). PKR will 
cause the phosphorylation of eIF2α on serine 51, resulting in an inactive complex 
between eIF2-GDP and eIF2B leading to a global inhibition of protein synthesis 
(73) (Fig. 2). Therefore, when PKR senses the presence of a viral infection in the 
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cell by detecting dsRNA, it can inhibit viral replication by limiting the synthesis 
of viral proteins required for replication. 
 An additional group of ISGs shown to enhance the innate immune 
system’s ability to respond to viral infections are the OAS proteins. Similar to 
PKR, the OAS proteins are activated by binding to the dsRNA produced during a 
viral infection (99). Viral dsRNA can directly activate one of several OAS 
proteins leading to the production of unique oligomers of adenosine with 2’, 5’-
linked phosphodiester bonds (63, 99). These 2’, 5’ oligoadenylates can then bind 
to a monomeric, inactive, cellular latent endoribonuclease, RNase L, inducing 
dimerization and activation of this protein (145) (Fig. 2). Active RNase L will 
induce RNA degradation of both cellular (rRNA, mRNA) and viral (mRNA) 
RNAs by cleaving single-stranded regions of RNA on the 3’ side of UpUp and 
UpAp dinucleotides (47). Through the degradation of cellular and viral RNAs, 
RNase L is able to induce an anti-viral state in infected cells by destroying the 
cellular machinery and the viral mRNAs required for viral replication.  
Furthermore, the small RNA fragments produced by RNase L can be recognized 
by RIG-I and MDA-5 and cause the induction of IFNα/β to further amplify and 
enhance the body’s ability to defend against a viral infection (78).   
 Viruses are intracellular obligate parasites that require the host’s cells for 
survival.  For this reason a majority of known viruses have evolved multiple 
strategies to evade and/or subvert many aspects of the host’s anti-viral immune 
response.  The members of the Poxviridae family of viruses are no exception; 
they utilize several different methods to interfere with and disrupt the host’s anti-
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viral immune response.  Poxviruses are large, linear double-stranded DNA viruses 
with a genome ranging from between 130 to 360 kbs and can encode for about 
200 different proteins (87).  Many of the genes are highly conserved among 
viruses within this family, especially those located near the center of the genome. 
This highly conserved region of poxvirus genomes contain genes required for 
viral transcription, replication, and assembly(133).  Genes located on the either 
termini of the genome are far less conserved and are not essential for replication, 
but they are known to play important roles in virulence, host range, and immune 
evasion (87).  What separates poxviruses from other known DNA virus families is 
their ability to replicate entirely in the cytoplasm of infected cells (86).  For this 
reason, poxviruses encode a majority of the factors required for transcription and 
replication of its own genome making them far less dependent on the cellular 
replication machinery required for the replication of many other DNA viruses.   
Perhaps the most widely studied genus within the family Poxviridae is the 
genus Orthopoxvirus. This is mainly due to the fact that one of the most 
significant human pathogens to ever exist, variola virus (VARV) the causative 
agent of smallpox, is a member of this genus. Within the genus Orthopoxvirus, 
there is an even greater conservation of genes. As a result, there is a high level of 
antigenic similarity among members of the genus Orthopoxvirus, which formed 
the foundation for vaccinating against smallpox, as one virus species could protect 
against an infection with another (121).  This theory was first reported by Edward 
Jenner in 1796, after treating patients with cowpox virus to protect them from 
contracting smallpox.  This method for vaccinating against smallpox eventually 
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became widely accepted by the international community and ultimately lead to 
the eradication of smallpox in the late 1970’s through to use of another member of 
the genus Orthopoxvirus, vaccinia virus (VACV) (121). 
 As stated previously, many viruses have evolved multiple strategies to 
circumvent the host’s immune system, and VACV is no exception.  Numerous 
VACV genes termed ‘virulence genes’ have been shown to interact with host 
proteins and they are capable of either affecting virus host range or the ability to 
evade the immune system (87, 109).  VACV is known to produce a viral 
complement control protein (VCP) that is capable of inhibiting both classical and 
alternative complement pathways (70-71).  Both pathways converge after the 
formation C3 convertase enzyme complex leading to induction of inflammatory 
cytokines and the destruction of the infected cells (87). VCP is able to block the 
complement pathways by binding to and inhibiting C3b and C4b from forming 
the functional C3 convertase enzyme complex (70).  Additionally, VCP has been 
shown to prevent complement-mediated antibody-dependent neutralization of 
VACV virions (56). VACV has also been shown to produce two proteins, B8R 
and B19R that interfere with IFN receptor signaling (125, 135).  B19R is a soluble 
IFN-α/β binding protein, whereas B8R is a soluble IFN-γ binding protein. Both of 
these proteins are secreted into the surrounding medium from infected cells; 
however, B19R has also been shown to be present on the surface of infected cells 
(3, 132).  The purpose of these proteins is to bind any soluble IFN molecules that 
may be present within the media and prevent them from binding to their receptors 
on non-infected or infected cells.  IFN binding will trigger a signaling cascade 
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that leads to an anti-viral state within the cell (95).  In addition to preventing IFNs 
from binding to their receptors, VACV also produces a number of other proteins 
that prevent the binding of other chemokines and cytokines such as IL-18 (119), 
tumor necrosis factor (TNF) (1), and IL-1β (2) to their respective cellular surface 
receptors.  These viral inhibitors ensure virus survival by counteracting the host’s 
anti-viral immune response.   
 VACV not only inhibits extracellular IFN signaling cascades, but it also 
has been shown to produce proteins that inhibit the intracellular signaling 
cascades.  Two proteins in particular, K3L and E3L, have been shown to interfere 
with the intracellular IFN signaling pathways responsible for inducing an anti-
viral state in an infected cell.  Deletion of K3L and especially E3L renders the 
virus sensitive to IFN and severely limits the host range of the virus (11-13). The 
VACV K3L gene encodes an eIF2α homologue that acts as a pseudosubstrate for 
PKR.  It is believed that K3L functions by binding to PKR and competitively 
inhibits the phosphorylation of eIF2α (11, 26).  By doing this, viral protein 
translation is allowed to continue unhindered.  
 The VACV E3L gene has been shown to be important for conferring the 
IFNR (IFN resistant) phenotype of VACV.  Functional studies have shown that 
transient expression of E3L and subsequent co-infection with known IFNS (IFN 
sensitive) viruses, vesicular stomatitis virus (VSV) and encephalomyocarditis 
virus (EMCV) for example, rescues the  IFNS phenotype of both viruses (113).  
The VACV E3L gene is highly conserved within the subfamily 
Chordopoxvirinae.  The E3L gene encodes for two proteins, p25 and p20, that 
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bind to dsRNA and sequester it away from many of the intracellular dsRNA 
PAMP sensors previously described (30, 137, 144).  The p25 form of E3L is 190 
amino acids in length and consists of two separate domains, an N-terminal Z-
nucleic acid binding domain (Z-NA-BD) and a C-terminal dsRNA binding 
domain (dsRNA-BD) (51-52) (Fig. 3).  The p20 form of E3L is missing the first 
37 amino acids from the N-terminus as a result of leaky scanning and translation 
initiation at a second downstream start codon (30, 144).  Deletion of the E3L gene 
leads to a loss of the VACV IFNR phenotype (11, 29), a restriction in viral host 
range (11, 13, 29), and a reduction in viral pathogenesis (20) .  In cells infected 
with a VACV deleted of E3L (VACV∆E3L), an inhibition of viral and cellular 
protein translation occurs through the activation of the PKR pathway and 
subsequent phosphorylation of eIF2α.  In addition, ribosomal RNA has also been 
shown to be degraded in VACV∆E3L infected cells due to the activation of the 
OAS-RNase L pathway (11).  It is believed that the loss of host range for 
VACV∆E3L may be linked to the induction of apoptosis in VACV∆E3L infected 
cells, a phenomenon that is not normally seen in cells infected with VACV 
expressing E3L (57). Most notably, VACV∆E3L is apathogenic in the C57BL/6 
mouse model when administered either intranasally or intracranially (20).   
Overall, the VACV E3L protein plays a pivotal role in aiding viral immune 
evasion of the host’s defenses.  
The C-terminal dsRNA-BD of E3L is highly conserved among many 
members of the subfamily Chordopoxvirinae (120).  This C-terminal domain is 
both necessary and sufficient for binding to dsRNA and sequestering it from the 
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cellular PAMP sensors (28-29). The dsRNA-BD of E3L has been shown to be 
responsible for establishing the IFNR phenotype and the broad host range of 
VACV, as well as being necessary for full pathogenesis in an animal model (20, 
28-29).  Mutations within this C-terminal domain generate a virus that is severely 
attenuated as compared to wild-type VACV (wt-VACV).  VACV expressing a 
form of E3L deleted of the last 26 amino acids from the C-terminus (VACV-
E3L∆26C) is unable to inhibit apoptosis in HeLa cells (65) and the virus is 
apathogenic in the C57BL/6 mouse model, similar to VACV∆E3L (20).   
Furthermore, E3L is able to bind directly to PKR through the C-terminal domain 
independent from the amino acids required for dsRNA binding (101, 112).     
It is believed that VACV generates dsRNA as a byproduct of overlapping 
convergent transcription (57).  VACV encodes genes on both strands of the 
genome and they are transcribed in three temporal stages, early, intermediate or 
late (35). Unlike early viral genes, the intermediate and late viral genes lack a 
transcription termination signal leading to the formation of long run-on 
transcripts.  If long complementary mRNAs are produced from genes transcribed 
in opposing directions they can potentially hybridize and form the dsRNA 
observed during a VACV infection (57).  The process of forming dsRNA during a 
VACV infection has been primarily characterized through the use of an anti-
poxvirus drug, isatin-β-thiosemicarbazone (IBT).  IBT is a non-cytotoxic 
compound capable of specifically inhibiting replication and plaque formation of 
numerous poxviruses (5, 36, 44, 60, 94, 139). It has no effect on the transcription 
of early genes, but IBT has been shown to increase read-through transcription that 
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results in longer than normal transcripts for the intermediate and late genes (97).  
Ultimately, IBT leads to an increase in dsRNA levels during a VACV infection 
and causes the activation of the OAS pathway leading to RNA degradation and 
inhibition of viral replication (34).  The exact mechanism of how IBT affects 
elongation and termination is unknown, but it is believed that IBT affects the 
processivity of the VACV RNA polymerase by either affecting subunits of the 
VACV RNA polymerase, (A24R and J6R), or elongation factors known to be 
involved in intermediate and late viral gene transcription, (A18R, G2R, J3R and 
H5R) (37-38). 
The N-terminal Z-NA-BD of E3L is fairly well conserved among many 
members of the subfamily Chordopoxvirinae, but to a lesser extent, as compared 
to the C-terminal dsRNA-BD.  The N-terminal domain of E3L shares homology 
with proteins known to bind to Z-form DNA (50), specifically the adenosine 
deaminase that acts on RNA (ADAR1).  ADAR1 is an ISG involved in post-
translational editing of RNA by the deamination of adenosine to inosine in 
dsRNA complexes, leading to a partial or complete unwinding of the dsRNA (9, 
93).  The structure of ADAR1 consists of two N-terminal nucleic acid binding 
domains, Zα and Zβ, a central region containing three dsRNA-BDs, and a C-
terminal deaminase catalytic domain (50).  The N-terminus of E3L shares partial 
homology to the Zα domain of ADAR1, the domain required for binding to Z 
form nucleic acid (50). Co-crystallization studies performed on the Zα domain of 
ADAR1 bound to Z-DNA showed 9 residues are important for contacting and 
binding to Z-DNA(108).  A protein sequence alignment of E3L and the Zα 
  12 
domain of ADAR1 shows E3L contains seven out of the nine conserved residues 
necessary for binding to Z-DNA (67).  E3L has been shown to bind to Z-DNA in 
vitro, but the interaction is weaker than that seen for the Zα domain of ADAR1 
(66).   
Initially, in vitro studies showed that a VACV expressing a form of E3L 
deleted of the first 83 amino acids from the N-terminus (VACV-E3L∆83N) has a 
host range and IFNR phenotype similar to wt-VACV (29, 113).  Even though the 
N-terminus of E3L is not required for replication in vitro, this domain is required 
for full pathogenesis in the C57BL/6 mouse model, as VACV-E3L∆83N is 1000-
fold less pathogenic than wt-VACV (19).  The loss in pathogenicity is not due to a 
decrease in viral replication, since the virus is able to replicate to high titers at the 
site of infection, but the virus failed to spread to the other tissues (i.e. lungs and 
brain) that normally support replication of wt-VACV (19).  Besides the loss in 
viral pathogenesis in vivo, there was no biochemical phenotype, in vitro, for 
VACV-E3L∆83N that allowed for an in-depth characterization of the E3L N-
terminus.  One exception is at late times post infection for a VACV-E3L∆83N 
infection of HeLa cells (~ 9 hpi), phosphorylation of eIF2α and PKR is detected. 
In contrast, no detectable levels of phosphorylated eIF2α or PKR are present in 
wt-VACV infected cells (75).  This suggests that the N-terminus of E3L may be 
required to inhibit the activation of PKR at late times post infection.   
Recent data shows that a complete N-terminal domain of E3L is necessary 
for full IFNR in mouse embryo fibroblasts (MEFs).  In MEFs, the N-terminus of 
E3L was required to completely inhibit the activation of the PKR (White and 
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Jacobs, submitted).  Additionally, the N-terminus has also been shown to be 
required for replication within the JC murine adenocarcinoma cell line (Trainor 
and Jacobs, in preparation).  Amino acid point mutations in E3L of known 
residues required for binding to Z-DNA affect the ability of VACV to replicate in 
JC cells.  Not only did binding to Z-DNA correlate with the ability to replicate in 
JC cells, but the same point mutations that decreased E3L’s affinity for Z-DNA 
also lead to a decrease in pathogenesis in the C57BL/6 mouse model (Trainor and 
Jacobs, in preparation).  This suggests that not only is the C-terminus of E3L 
required for full IFNR and pathogenesis of VACV, but so is the N-terminus and 
mutations within any of these domains can severely attenuate VACV. 
VACV was used extensively as the vaccine to protect against a smallpox 
infection.  As a result, much of the biology associated with how VACV protects 
against smallpox and the side effects associated with vaccination have been fairly 
well characterized.   The downside of using a VACV as a vaccine was that there 
were many side effects associated with the virus and a significant portion of 
today’s population would not be allowed to receive the vaccine due to these 
adverse side effects.  However, due to the successful eradication of smallpox by 
VACV, an interest in using attenuated strains of VACV as a vaccine platform to 
prevent or treat other diseases has been gaining popularity.  As previously 
described, N-terminal and C-terminal mutations in the VACV E3L protein can 
lead to virus attenuation and a decrease in viral pathogenesis.  Therefore, 
attenuated strains of VACV with mutations in the E3L protein may provide a 
basis for developing other VACV based therapies. The marked attenuation of 
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VACV E3L mutants may reduce the side effects associated with the wild-type 
vaccine and allow the majority of the population to be vaccinated or treated with 
these VACV mutants (20, 136).  
One potential use for attenuated VACV with mutations in the E3L protein 
is as an oncolytic virus to treat the different forms of cancer. Oncolytic viruses are 
microorganisms that have been selected and/or engineered to grow within 
cancerous cells, while sparing the normal non-cancerous cells.  It is well known 
that most cancerous tumors arise through genetic mutations in a cell that alter 
normal cellular processes and allow for uncontrolled cellular replication.  Many of 
these mutations result in the dysregulation of cellular anti-proliferative and anti-
apoptotic pathways that normally prevent unrestricted cell growth.  Oncolytic 
viruses can be designed to specifically target cancer cells by exploiting those 
same cellular pathways that aid in tumor growth. One strategy currently being 
developed is to design viruses that would take advantage of deficiencies in 
cellular anti-viral defense pathways, a phenomenon that seems to be altered in 
many types of cancer.  For example, the IFN anti-viral response pathway has been 
shown to be dysregulated in many types of cancers (122).  It is generally accepted 
that IFNs possesses both anti-viral and anti-proliferative activities with a cell.  
Interferon-sensitive viruses have already been shown to be effective in treating 
some types of cancer based on their ability to selectively replicate in cancer cells 
that have a nonfunctional IFN anti-viral response pathway.  Herpes virus, 
influenza virus, newcastle disease virus (NDV), reovirus, poliovirus, measles 
virus and vesicular stomatitis virus (VSV) have all demonstrated the ability to 
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propagate more efficiently in cancer cells than in normal IFN-responsive cells 
(102, 134).  These viruses are either naturally selective for IFN-deficient cells 
(VSV, NDV, reovirus) or they were engineered to specifically target cancerous 
cells (Herpes virus, influenza virus, poliovirus, and measles virus). 
ISGs not only have anti-viral properties, but they also play roles in 
controlling cellular proliferation and induction of apoptosis (91).  Therefore, it is 
not unexpected for cancerous cells to develop defects in their ability to respond to 
IFN.  In particular, PKR deficiencies have been shown to be vital for oncolytic 
virus replication within some types of cancerous cells (27, 45, 122, 124).  For 
many cancer cell types, PKR inhibition has been shown to be associated with an 
overactive Ras pathway by either Ras acting directly on PKR or by Ras inducing 
an inhibitor of PKR, the Ras-induced kinase inhibitor (RIKI) (33, 88).   
Mutations in Ras proteins are associated with approximately 50% of colon 
cancers, 90% of pancreatic cancers, and 25% of other types of human cancers (16, 
25, 82, 118).  The levels of activated Ras in gliomas in particular are similar to 
those seen in other types of cancer, but gliomas do not contain oncogenic forms of 
Ras (49, 131).  It is believed that an overexpression of the epidermal growth 
factor receptor (EGFR) and the platelet-derived growth factor receptor (PDGFR), 
through over-activation of their adapter signaling proteins, is responsible for 
causing this hyperactivation of the Ras pathway in glioblastoma cancer cells (49).  
It is these overactive Ras pathways through either direct mutations within the Ras 
protein or indirectly through upstream regulators of Ras, that may provide one 
approach to successfully design an oncolytic virus that is selective for cancerous 
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cells.  In the second chapter of this dissertation, we demonstrate the development 
of an oncolytic VACV expressing a form of E3L that contains a partial deletion of 
the N-terminal Z-NA-BD.  This virus is able to destroy cancerous cells in vitro 
and cause tumor regression in vivo. 
Deletions within the N-terminus of E3L or its homologues do not 
necessarily result in the virus attenuation.  Within the subfamily 
Chordopoxvirinae, monkeypox virus (MPXV) and the leporipox viruses are the 
only viruses known to contain versions of the VACV E3L protein with 
truncations in the N and C-terminal domains.  These viruses are still pathogenic in 
their respective hosts even though they contain deletions in their E3L homologues 
that have been shown in the past to result in attenuation.  At this time it is unclear 
how these viruses, specifically MPXV, is able to overcome the changes in their 
E3L homologues and still induce pathogenesis.   
The first human cases of MXPV infections were diagnosed in the Congo 
region of Africa in 1970 (79).  It is believed that MPXV infections may have been 
occurring in Africa for centuries, under the guise of smallpox (VARV) infections. 
Since the symptoms associated with a MPXV infection closely resemble those of 
VARV, it was not until VARV was eradicated that more cases of human MPXV 
infections began to arise. MPXV is endemic in the West and Central areas of 
Africa, with a majority of the cases detected in the Congo Basin (Central) 
countries of Africa (54).  The fatality rate associated with MPXV infections in 
endemic areas is approximately 10%, compared to 30% for VARV infections 
(32).  Data from a World Health Organization (WHO) surveillance program from 
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1981 to 1986 revealed 404 cases of MPXV infections occurring sporadically 
throughout Central and Western Africa, mainly due to transmission of the virus 
from animals to humans. Human-to-human spread was relatively rare and only 
accounted for about 28% of the cases. The secondary attack rate, the measure of 
human-to-human transmission, for most isolates of MPXV is about 9%, unlike 
smallpox which is close to 60% (32).  In 2003, a hospital in Africa reported six 
sequential human-to-human transmissions of MPXV suggesting that the 
transmission efficiency for MPXV may be increasing (92).  The number of human 
MPXV infections also appears to be increasing with 500 reported cases in 1997 
and 1,265 reported cases between 1998 to 2002 worldwide (92).  MPXV has 
gained additional attention since 2003, when the first human cases of MPXV 
infections were identified in the Midwestern United States (100). 
Currently there are two strains of MPXV identified, ones that originated 
from West Africa and ones that originated from Central Africa.  Genomic 
sequencing of several Central and West African MPXV strains revealed they were 
95% identical at the genetic level, while at the protein level they are on average 
99% identical (32).  West African strains are known to cause a milder form of the 
disease, as they usually do not result in fatalities and are less likely to be 
transmitted from human-to human.  However, the Central African strains of 
MPXV are known to have a fatality rate of about 10% with a higher probability of 
human-to-human transmissions (32). Since the West African strains have been 
shown to be less virulent, a comparison of the 56 known virulence gene revealed 
that 53 of the genes were conserved between West African and Congo Basin 
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strains, while three others were either completely deleted or fragmented in the 
West African strains (32).  It is believed that these mutations are responsible for 
the virulence variability observed between these two strains of MPXV.   
The first outbreak of MPXV in the Western hemisphere appeared in 2003 
with 37 confirmed cases occurring in the Midwestern United States (100).  No 
fatalities or human-to-human transmissions were reported during this outbreak.  
MPXV infections were traced back to six African giant rats imported from Ghana, 
who were housed with domestic black-tailed prairie dogs resulting in the prairie 
dogs contracting the virus.  The human cases of MPXV associated with this 
outbreak were believed to occur through direct contact with the infected prairie 
dogs (100).  DNA sequencing of the U.S. isolates showed they were more closely 
related to the West African strains of MPXV, rather than the more virulent 
Central African strains. This may offer one explanation as to why no human 
fatalities were associated with this outbreak of MPXV in 2003 (100). 
With the eradication of smallpox and the cessation of the human smallpox 
vaccination program, there is a growing concern that VARV (smallpox) and 
MPXV could be employed as a biological weapon.  This is especially 
disconcerting, given that today’s human population has relatively low or 
nonexistent immunity to smallpox (22, 79). The use of VACV (smallpox vaccine) 
to protect against a MPXV infection has shown to be 85% effective in preventing 
disease (46), but it is highly unlikely that it will be used as a pre-exposure 
vaccine, due to severe side effects associated with vaccination.  For these reasons 
there is an increasing interest in gaining a better understanding of why MPXV is 
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able to cause disease in humans.  In particular, a better understanding of how 
MPXV is able to circumvent the host’s IFN anti-viral immune response could 
provide a better platform to design more efficient vaccines capable of protecting 
against both monkeypox and smallpox infections.  
As previously described, VACV has been shown to contain two proteins 
known to play roles in inhibiting the cellular IFN anti-viral immune response, 
E3L and K3L.  The E3L protein is able to bind dsRNA and sequester it away 
from known PAMPs (PKR, RIG-I MDA-5, and OAS), thereby preventing their 
activation (30, 137, 144).  K3L has been shown to act as a pseudosubstrate for 
PKR to prevent autophosphorylation and activation (26).  Ultimately, these two 
VACV proteins prevent the shutdown of host cellular protein translation by 
inhibiting the phosphorylation of eif2α by PKR.  The VACV E3L has also been 
shown to inhibit the OAS pathway that induces cellular and viral mRNA 
degradation in response to a viral infection (11).  
Genomic comparisons between MPXV and VACV show significant 
similarity between these two viruses. One MPXV protein in particular, F3L, is 
believed to be an homologue of the VACV E3L protein with a nucleotide and 
protein sequence similarity of 75% and 72%, respectively. The VACV E3L 
protein contains two conserved domains; an N-terminal Z-nucleic acid binding 
domain (Z-NA) and a C-terminal dsRNA binding domain.  Both of these domains 
have been shown to be necessary for wild-type pathogenesis in a mouse model, as 
well as full IFNR in vitro (20) (White and Jacobs, submitted).  It’s believed that 
the F3L protein of MPXV contains a complete C-terminal dsRNA binding 
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domain, while the Z-NA binding domain is deleted of the first 37 amino acids 
from the N-terminus.  In addition, MPXV is also believed to contain a partial 
deletion in the VACV K3L homologue resulting in a non-functional K3L protein.  
Not only do these proteins play a role in inhibiting the IFN response, they have 
also been shown to affect the host range of VACV.  In particular, a deletion of 
K3L has been shown to affect the ability of VACV to replicate in baby hamster 
kidney cells (BHK-21) (76).  MPXV is classified as having a broad host range 
with the ability to infect a wide range of cell types and hosts (92). Therefore, the 
main objective in the first chapter of this dissertation was to analyze the ability 
MPXV to inhibit the IFN anti-viral immune response.  It is unclear whether the 
combination of the N-terminal truncation within F3L and inability of the virus to 
generate a functional K3L protein causes MPXV to possess IFNR and host range 
phenotype similar to that seen for VACV.  We show that MPXV has an IFNR 
phenotype similar to wt-VACV and it is able to inhibit the cellular anti-viral 
immune response to a greater extent than a VACV mutant containing an 
equivalent N-terminal truncation in E3L.    
  
   
Fig. 1. TLR and RIG-I/MDA-5 Pathways.  TLRs 3, 7, 8, and 9 present 
within endosomes are activated during viral infection through recognition 
PAMPs such as dsRNA, ssRNA, or CpG DNA.  Once activated, TLR 3 signals 
through TRIF, whereas TLR 7, 8, or 9 signal through MyD88. Activation of the 
TLR pathways results in the activation IFR-3 or IFR-7, triggering an induction of 
IFN-α/β transcripts. RIG-I and MDA-5 singnaling pathways are activated 
through recognition of ssRNA or dsRNA triggering a signaling cascade involving 
proteins IPS-1 TRAF3 and TBK-1/IKKε.  Similar to the TLR pathway, activation 
of the RIG-I and MDA-5 pathways result in an induction of IFN-α/β transcripts. 
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Fig. 2. IFN Inducible PKR and 2’,5’ OAS Pathways.  INFα/β induces 
numerous ISGs such as PKR and 2’,5’ OAS.  During a viral infection dsRNA 
is generated as a byproduct of convergent viral transcription. PKR and 2’, 5’ 
OAS become activated upon binding to dsRNA.  Activated PKR will induce 
the phosphorylation of the α-subunit of eIF2, which leads to an inhibition of 
protein synthesis. 2’,5’ OAS will activate RNase L, leading to a degradation 
of cellular and viral RNA, eventually leading to an inhibition of protein 
synthesis.  
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Fig. 3. Biochemical Domains present within VACV-E3L.  The VACV-
E3L gene encodes two proteins, designated p25 and p20. Full length p25 is 190 
amino acids and p20 contains a natural 37 amino acid truncation from the N-
terminus. The N-terminus contains a Z-NA binding domain (BD), while the C-
terminus contains the dsRNA BD.  Both full length domains are required for 
pathogenesis within an animal model, as well as, for complete inhibition of 
PKR and IFN resistance.  
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CHAPTER 1 
MONKEYPOX VIRUS PREVENTS THE ACTIVATION OF THE CELLULAR 
ANTI-VIRAL IMMUNE RESPONSE  
ABSTRACT 
 Viruses require host cells for replication and have evolved multiple 
mechanisms to overcome many of the host’s anti-viral immune response used to 
defend against a viral infection.  Vaccinia virus (VACV) is known to contain 
proteins involved in overcoming the cellular anti-viral immune response.  For 
example, the VACV E3L and K3L proteins have been shown to be important for 
blocking activation of the cellular innate immune system and allowing for viral 
replication to occur unhindered.  Mutations or deletions of these genes severely 
affect viral host range and pathogenesis.  Monkeypox virus (MPXV) encodes 
homologues of the VACV E3L and K3L proteins; however, the E3L homologue 
of MPXV, F3L, has a 37 amino acid N-terminal truncation.  In addition, MPXV 
encodes a non-functional K3L protein.  This suggests that MPXV should be 
severely attenuated; nonetheless, MPXV has a higher mortality rate in humans 
than VACV.  The data presented in this chapter show that MPXV is able to inhibit 
the anti-viral immune response similar to wild-type VACV allowing for full 
inhibition of PKR and the ability to replicate in JC cells.  In addition, we show 
that MPXV produces less double-stranded RNA (dsRNA) during the course of an 
infection.  Together, these data help explain why MPXV possesses a phenotype 
more similar to wild-type VACV, rather than a VACV containing the equivalent 
truncation in E3L.  
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 INTRODUCTION  
 
There is a growing concern that variola virus (VARV, smallpox) or 
MPXV could be employed as a biological weapon.  This is especially 
disconcerting, given that today’s human population has relatively low immunity 
to smallpox (22, 79). The use of VACV (smallpox vaccine) to protect against 
MPXV infection has shown to be 85% effective in preventing disease (46); 
however, it is highly unlikely the current vaccine will be used as a pre-exposure 
vaccine, due to severe side effects associated with vaccination.  In hopes of 
developing a better vaccine to protect against smallpox and MPXV infections, 
there is an increasing interest in gaining a better understanding of how MPXV is 
able to cause disease in humans.  In particular, a better understanding of how 
MPXV is able to circumvent the host’s anti-viral immune response may provide a 
better platform to design more efficient vaccines capable of protecting against 
both monkeypox and smallpox infections. 
To gain a better understanding of the increased pathogenicity associated 
with MPXV, we decided to look at the differences in genes known to be involved 
with viral immune evasion, specifically the VACV E3L and K3L homologues 
present in MPXV.  As described previously, VACV contains two proteins that 
play roles in preventing activation of the cellular IFN anti-viral immune response, 
E3L and K3L (11-13).  The E3L protein is able to bind dsRNA and sequester it 
away from known PRRs (PKR, RIG-I MDA-5, and OAS), thereby preventing 
their activation (30, 137, 144).  K3L has been shown to act as a pseudosubstrate 
for PKR to prevent autophosphorylation and activation of this cellular protein 
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(26).  Ultimately, these two VACV proteins prevent the global inhibition of 
protein translation by inhibiting the phosphorylation of eif2α by PKR.  VACV 
E3L has also been shown to inhibit the OAS pathway, which leads to cellular and 
viral RNA degradation in response to a viral infection (11). 
Both of these viral proteins can inhibit the cellular IFN anti-viral immune 
response, by either directly blocking the activation of PKR or by preventing 
active PKR from binding to its normal substrate (eIF2α).  With regard to K3L, 
deletion of K3L from VACV can affect IFN resistance of VACV in certain cell 
lines, specifically L929 and BHK cells (14, 76). In IFN pretreated L929 cells, the 
replication of a recombinant VACV deleted of K3L (VACV∆K3L or vP872) was 
inhibited.  Viral protein synthesis was inhibited in these cells confirming the 
importance of K3L in blocking the anti-viral immune response.  A deletion of 
K3L was also shown to affect the host range of VACV.  Replication and viral 
protein synthesis in VACV∆K3L infected BHK cells was significantly decreased 
as compared to VACV infected cells (76). 
Both N-terminal and C-terminal domains of the VACV E3L protein have 
been shown to be necessary for the complete inhibition of the PKR pathway (75).   
In vitro studies show that two VACV recombinants, VACV-E3L∆83N and 
VACV-E3L∆37N (p20, deleted of the first 37 amino acids from the N-terminus) 
have a host range and IFNR phenotype similar to wt-VACV (29, 113).  However, 
in a mouse model VACV-E3L∆83N is 1,000-fold less pathogenic, while VACV-
E3L∆37N pathogenesis is reduced by 1,000-fold during an intracranial infection 
and 100-fold during an intranasal infection, as compared to VACV (19).  There is 
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no in vitro biochemical phenotype for VACV-E3L∆83N and VACV-E3L∆37N 
that allow for an in-depth characterization of the E3L N-terminus.  However, 
phosphorylation of eIF2α was detected for both viruses at late times post infection 
(~9 hpi), while phosphorylation of eIF2α was not present in wt-VACV infected 
HeLa cells (75).  This suggests that the N-terminus of E3L may be required to 
inhibit the activation of PKR at late times post infection for VACV.   
Genomic comparisons between MPXV and VACV show great similarity 
between these two viruses. The MPXV protein, F3L, is believed to be an 
homologue of the VACV-E3L protein. The VACV-E3L protein contains two 
conserved domains; an N-terminal Z-nucleic acid binding domain (Z-NA) and a 
C-terminal dsRNA binding domain.  Both of these domains have been shown to 
be necessary for wild-type pathogenesis in a mouse model, as well as full IFNR in 
vitro (20), (White and Jacobs, submitted).  However, based on a protein sequence 
alignment between the VACV E3L and MPXV F3L proteins, it is believed that 
the F3L protein of MPXV contains a complete C-terminal dsRNA-BD, while the 
Z-NA-BD is deleted of the first 37 amino acids from the N-terminus (Fig. 4).  In 
addition, MPXV also contains a partial deletion in the sequence of the VACV-
K3L homologue, resulting in a non-functional protein.  Not only do these proteins 
play a role in inhibiting the IFN response, but they also have been shown to affect 
the host range of VACV.  For example, VACV deleted of K3L has been shown to 
affect virus’ ability to replicate in BHK-21 cells (76). MPXV is classified as 
having a broad host range with the ability to infect a wide range of cell types and 
hosts. Thus, it is unclear whether this combination of the F3L N-terminal 
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truncation and inability of the virus to generate a functional K3L protein would 
permit MPXV to possess an IFNR and host range phenotype similar VACV or one 
of the VACV N-terminal mutants. 
In this work we demonstrate the gene coding for the MPXV E3L 
homologue, F3L, produces a protein truncated of the first 37 amino acids from the 
N-terminus. In addition, the F3L protein was able to restore the IFNR phenotype 
for a VACV containing a deletion of E3L. We have shown previously, that a 
complete N-terminus of E3L and the ability to bind Z-form nucleic acid were 
necessary for replication in JC cells.  For the first time we demonstrate that the 
complete N-terminal Z-NA-BD is not necessary for replication in JC cells, as 
MPXV replicates to similar levels as VACV.  Furthermore, we show herein that 
less dsRNA is generated during an MPXV infection as compared to VACV. 
Therefore, we hypothesize that the decrease in dsRNA levels allows MPXV to 
replicate in JC cells and have an IFNR phenotype similar to VACV, thereby 
compensating for the loss of the F3L N-terminus in MPXV. 
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MATERIALS AND METHODS 
Cells and Viruses.  Vero-E6, baby hamster kidney (BHK-21), Rabbit 
Kidney (RK)-13, and RK-E3L cells were maintained in Eagle’s Minimal 
Essential Medium (MEM, Cellgro) supplemented with 5% fetal bovine serum 
(FBS) (HyClone). HeLa and BSC40 cells were maintained in Dulbecco’s 
Modified-Minimal Essential Medium (DMEM) (Cellgro) supplemented with 5% 
FBS.  JC (murine adenocarcinoma) cells were maintained in RPMI (ATCC) 
supplemented with 10% FBS. All cells were incubated at 37°C in the presence of 
5% CO2.  For IFN treatment, cells were pretreated with the appropriate amount of 
human α A/D interferon (IFN-α A/D) (PBL) at 37°C for 18 hours. Vaccinia virus 
Copenhagen (VC-2) and Western Reserve (WR) strains, designated as VACV, 
were used as the parental viruses for all the recombinant viruses used throughout 
this study. VACV deleted for E3L (VACV∆E3L) and VACV containing a 37 
amino acid N-terminal truncation of E3L (VACV-E3L∆37N) were generated as 
previously described (29, 114). Monkeypox virus Walter Reed 267 strain 
(MPXV), was used as the parental to generate the recombinant MPXV used in 
this study.  All MPXV experiments were completed in a biosafety level 3 
laboratory (BSL-3) in accordance with protocols approved by Arizona State 
University and the Centers for Disease Control and Prevention (CDC).  For all 
HeLa and Vero-E6 cell infections, Copenhagen strains of vaccinia were used, 
whereas for all JC cell infections, Western Reserve strains were used. 
Plasmids.  The F3L protein of MPXV was amplified from MPXV viral 
DNA through PCR with primers containing a BamHI site at the 5’end and a 
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HindIII site at the 3’end of the gene using forward primer (5’ GAG GAT CCA 
ATA TGG AGA AGC GAG AAG 3’) and reverse primer (5’ GGC GCG AAG 
CTT TCA GAA TCT AAT GAT GAC 3’) sets. The PCR product was purified 
using the Wizard® SV Gel and PCR Clean up system (Promega) according to 
manufacturer’s instructions and digested with BamHI and HindIII (New England 
Biolabs).  Fragment were ligated into the in vitro recombination vector 
pMPE3∆GPT-MCS (65), resulting in the formation of  pMPE3∆GPT-F3L.  
Transfection and In vivo Recombination.  In vivo recombination was 
performed in BHK-21 cells as described previously (19). Transfections were 
performed using Lipofectamine™ (Invitrogen) in conjunction with PLUS™ 
Reagent (Invitrogen) to enhance transfection efficiency.  BHK-21 cells were 
transfected according to the manufacture’s protocol with pMPE3∆GPT-F3L or 
pMPE3∆GPT-lacZ and infected with VACV∆E3L or MPXV at a multiplicity of 
infection (MOI) of 0.05, respectively.  At 48 hours post infection (hpi), the cells 
were harvested and the recombinants were subjected to mycophenolic acid (MPA) 
selection as described previously (20, 65).  Plaques were identified by X-Gal 
staining, which resulted in blue plaques.  Two rounds of plaque purification were 
performed in the presence of MPA, followed by three rounds of purification in the 
absence of MPA to allow for resolution of the plasmid.  All viruses were 
amplified in BHK-21 cells.  The recombinant VACV containing the F3L protein 
of MPXV will be referred to as VACV∆E3L:F3L.  VACV∆E3L:F3L was 
generated for both Copenhagen and WR strains of VACV. The recombinant 
MPXV, which contains lacZ in the place of F3L, will be referred to as 
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MPXV∆F3L.  CDC approved the generation of all MPXV recombinants 
described in this dissertation. 
Interferon Sensitivity Assay. Vero-E6 and RK-13 cells were seeded in 6 
well plates and pretreated with 0, 1, 10, 100, and 1,000 IU/ml of IFN-α A/D. Cells 
were infected with 150 pfu of MPXV and incubated at 37°C in the presence of 
5% CO2 for 72 hours. Plaques were visualized by staining with 0.1% crystal 
violet in 20% ethanol solution. 
Single-cycle Growth Kinetics.  HeLa and Vero-E6 cells were seeded in 6 
well plates so they would be 80% confluent at the time of infection. The cells 
were infected with VACV, VACV∆E3L, VACV-E3L∆37N, MPXV, and VACV-
F3L at a MOI of 5. Infected cells were harvested at 3, 6, 9, 12, 15, 18 and 24 hpi. 
Titers for VACV, VACV recombinants, and MPXV were determined by plaque 
assay and crystal violet staining in Vero-E6 cells. 
Multi-cycle Growth Kinetics.  HeLa, Vero-E6, and JC cells were seeded 
in 6 well plates so they would be 80% confluent at the time of infection. The cells 
were infected with VACV, VACV∆E3L, VACV-E3L∆37N, MPXV, and VACV-
F3L at a MOI of 0.01. Infected cells were harvested at 3 and 72 hpi. Viral titers 
for VACV, VACV recombinants, and MPXV were determined as described 
above.  
PKR and eIF2α Phosphorylation.  Sub-confluent HeLa cell monolayers 
were infected with VACV, VACV∆E3L, VACV-E3L∆37N, MPXV, and VACV-
F3L at a MOI of 5 in the presence or absence of 1,000 IU/ml of human α A/D 
interferon (PBL). At the indicated times post infection, RIPA cell lysates were 
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prepared.  Cells were scraped into 1 ml of 1X phosphate buffered saline (PBS) 
and pelleted by centrifugation at 1,000 x g at 4°C for 10 min. The cell pellet was 
resuspended in 75 µL of RIPA buffer (1X PBS, 1% NP40, 0.5% sodium 
deoxycholate, 0.1% SDS, 200 mM NaF, 2 mM Na3VO4) for 10 min followed by 
centrifugation at 10,000 x g for 10 min. Supernatants were removed and an equal 
volume of 2X SDS-PAGE loading buffer (125 mM Tris-Cl, 20% glycerol, 4% 
SDS, 0.001% bromphenol blue, 0.2% 2-mercaptoethanol) was added. The 
samples were boiled for 5 min and analyzed on 12% SDS-PAGE gels. Proteins 
were transferred to polyvinylidene fluoride membrane (PVDF) at 100 volts for 60 
min in 10 mM CAPS, pH 11 with 20% methanol. The membranes were blocked 
with TTBS (20 mM Tris-HCl, pH 7.8, 180 mM NaCl, 0.05% Tween-20) + 3% 
milk (Carnation® Non-fat Dry Milk) for 1hr. The membranes were probed with 
rabbit anti-phospho-PKR (1:1000, Epitomics), rabbit anti-PKR (1:1000, 
Epitomics), and rabbit anti- phosphor-eIF2α (1:1000, Epitomics).  Secondary goat 
anti-rabbit IgG conjugated to horseradish peroxidase (1:10,000, Santa Cruz) was 
added followed by chemiluminescence. All lysates were also probed by western 
blot with goat anti-rabbit GAPDH to confirm an equal loading of samples.  
Immunofluorescent Microscopy.  HeLa cells were seeded on poly L- 
lysine treated coverslips in 6 well dishes and JC cells were seeded onto 
fibronectin treated coverslips in 6 well dishes.  HeLa and JC cells were infected at 
a MOI of 5 with VACV, VACV-E3L∆37N, and MPXV.  At 3, 6, 9, and 12 hpi 
the cells were rinsed twice with PBS.  Subsequently, ice cold methanol was added 
and the cells were placed at -20ºC for 20 minutes.  The cells were then washed 
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twice with ice cold PBS and blocked with blocking buffer (0.3% gelatin in PBS, 
0.1% triton X-100) at room temperature for 30 minutes.  Primary antibody [mouse 
monoclonal, J2 anti-dsRNA (107)] was diluted in 0.3% gelatin, 0.1% triton x-100 
in PBS (GTPBS) and incubated overnight at 4°C.  The cells were then washed 
five times with GTPBS for 10 minutes/wash.  The second primary antibody 
(rabbit polyclonal anti-E3L) was diluted in GTPBS and the procedure was 
repeated.  Secondary antibodies [Alexa Fluor 488 and 594 (Invitrogen)] diluted in 
GTPBS were added and incubated for 1 hour at room temperature in the dark.  
After incubation, the cells were washed 3 times with GTPBS for 10 
minutes/wash, then twice with PBS.  4’6diamino-2-phenylindole (DAPI) 
(Invitrogen) was added at a concentration of 5 µg/mL for 15 minutes at room 
temperature in the dark.  The cells were rinsed with ddH2O and then mounted onto 
slides with ProLong Gold antifade mounting reagent (Invitrogen).  The samples 
were allowed to cure overnight.  Samples were analyzed using the Zeiss Duo 
confocal microscope.   
Real-Time PCR.  HeLa and JC cells were infected at a MOI of 5 with 
VACV, VACV-E3L∆37N, and MPXV.  Total RNA was extracted 1, 2, 4, 6, 8, 
10, and 12 hpi using the RNeasy Mini Kit (Qiagen) according to manufacturer’s 
instructions.  cDNA was generated with 500 ng of total RNA diluted in 17.5 µL 
of H2O (RNase, DNase free) followed by addition of 1 µL Oligo dT (500 µg/mL, 
Promega) and incubation at 70°C for 5 min. Samples were then chilled on ice and 
the Revese-Transcription mix (10 µL – 5X M-MLV Real Time PCR Buffer 
(Promega), 20 µL – 1mM dNTPs, 1 µL – M-MLV Reverse Transcriptase (200 U/ 
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mL, Promega), 0.5 µL - RNasin® Plus RNase Inhibitor (40 U/µLPromega)] was 
added.  The samples were incubated at 37°C for 1 hr and 95°C for 10 min, and 
then placed on ice.  Real Time PCR was performed with MJ Mini (BioRad) 
thermocycler under the following condition: 95°C - 10 min, and 35 cycles at 95°C 
- 15 sec, 55°C - 30 sec, and 72°C - 30 sec. Two hundred ng of cDNA was added 
to Real Time PCR mix (12.5 µL – 2X iQ SYBR Green Supermix (BioRad) and 
2.5 µL – 10 mM Forward and Reverse Real-Time primers, 5.5 µL – ddH20 for a 
total volume of 25 µL). VACV and MPXV M1L transcripts were detected with 
primer pairs M1L-F (5’ – AAC GGA CCA CAT CCT TCT TC – 3’) and M1L-R 
(5’ – ATC CAA ACG CGT GTG ATA AA – 3’).  VACV and MPXV G8R 
transcripts were detected with primer pairs G8R-F (5’ – GCG GAT CTG TAA 
ACA TTT GG – 3’) and G8R-R (5’ – CCT TGG ACA CAG GAA GAT TAA A 
– 3’) and the MPXV specific primer, MPXV-G8R-R (5’ – CCT TGG ACA CTG 
GAA GGT TAA A – 3’).  VACV A5L transcripts were detected with primer pairs 
A5L-F (5’ – TTT CCA TCC GAT TGT TGT GT – 3’and A5L-R (5’ – AGT TCA 
CTC CTT CCA GCG TT – 3’) and MPXV A5L transcripts were detected with 
MPXV specific primer pairs, MPXV-A5L-F (5’ – CTT CCA TCC GAT TGT 
TGT GT – 3’) and MPXV-A5L-R (5’ –AGT ACA CTC CTT CCA GCG TT – 
3’). For VACV and MPXV genome Real-Time PCR, 500 ng of DNA was added 
to the Real Time PCR mix and the same thermocycling conditions and G8R 
primer sets were used as described above.  GAPDH (HeLa) and β-actin (JC) were 
used as internal loading controls and standardization between samples using the 
primer pairs GAPDH-F (5’ – CCT GTT CGA CAG TCA GCC G – 3’) and (5’ – 
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CGA CCA AAT CCG TTG ACT CC– 3’) and β-actin-F (5’– CGG GAC CTG 
ACA GAC TAC CTT – 3’) and β-actin-R (5’ – ATT TCC CTC TCA GCT GTG 
GT– 3’), respectively. 
 Slot Blot for dsRNA.  Total RNA was extracted from HeLa cells infected 
with VACV, VACV-E3L∆37N, and MPXV using the RNeasy Mini Kit (Qiagen). 
An equal volume of total RNA (2 µL) was diluted in ddH20 (198 µL).  Diluted 
RNA was applied through a VacuSlot VS manifold and transferred onto Hybond-
N+ (Amersham Pharmacia Biotech) positively charged membrane. The 
membrane was UV crosslinked with a Stratagene Stratalinker 1800 (Stratagene). 
Western blot analysis was performed was performed with J2 monoclonal dsRNA 
antibody was used as the primary antibody for detection of the dsRNA.   
ELISA for Detection of dsRNA.  Microtiter plates were coated overnight 
at 4°C with 0.4 μg protein A per well. Free binding sites on the plates were 
blocked with 2% bovine serum albumen (BSA) in PBS. The plate was washed 
with 1X PBS and stored at 4°C. Plates were incubated with J2 mouse monoclonal 
dsRNA capture antibody (1 μg/mL, IgG2a, English Scientific Consulting) in 
ELISA binding buffer (0.1M Na2HPO4, pH 9.0) overnight at 4°C. Plates were 
then blocked for 2 hrs at room temperature with ELISA blocking buffer (PBS, 1% 
BSA), followed by washing three times with ELISA wash buffer (PBS, 0.05% 
Tween-20). Five hundred ng of total RNA was diluted in ELISA dilution buffer 
(blocking buffer + 0.05% Tween-20) to a final volume of 100 μL.  The diluted 
RNA was added to the wells and allowed to incubate overnight at 4°C. Plates 
were then washed 4 times with wash buffer followed by incubation for 2 hours at 
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room temperature with the dsRNA detection antibody (K2, IgM, hybridoma 
supernatant diluted 1:4 in blocking buffer + 0.05% Tween-20, English Scientific 
Consulting). The plate was then washed 4 times with wash buffer, followed by 
incubation with anti-mouse IgM antibody (1:1000 in blocking buffer + 0.05% 
Tween-20, Santa Cruz Biotechnology) conjugated to HRP for 30 min. The plates 
were subsequently washed 5 times with wash buffer followed by addition of 100 
μL/well of SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific). dsRNA signal was quantified by Luminescent plate reader. 
In Vitro PKR Kinase Assay.  Semi-confluent monolayers of HeLa and JC 
cells were infected with VACV, VACV-E3L∆37N, or MPXV at a MOI of 5. 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) at 1, 6, and 12 hp, 
according to manufacturer’s instructions. For cytoplasmic extracts of PKR, HeLa 
cell monolayers were washed and scraped into ice cold PBS. The cells were 
pelleted by centrifugation at 1,000 x g for 10 min at 4°C and resuspended in 
Nonidet P-40 lysis buffer [20 mM HEPES, pH 7.5, 120 mM KCl, 5 mM MgCl2, 1 
mM dithiothreitol (DTT), 10% (vol/vol) glycerol, 0.5% Nonidet P-40] at a 
volume of 100 uL per 100 mm dish of cells at 80% confluentcy. Nuclei and cell 
debris were removed by centrifugation at 10,000 x g for 10 min at 4°C. 
Cytoplasmic extracts were stored on ice, until needed.  Ten µg/mL of poly-[I:C] 
was used or 500 ng of total RNA or was added to in vitro kinase buffer (5 mM 
MgOAc, 5mM MnCl2, 20 mM HEPES, pH 7.5, 10% Glycerol, 100mM KCl, 
1mM DTT, 1mM Benzamidine, 100μM ATP).  A 30 µL reaction containing 10 
μL of NP-40 extract and the 500 ng of total RNA was added to the in vitro kinase 
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buffer and incubated at 30°C for 10 min, after which 30 μL of 2X SDS-PAGE 
loading buffer was added.  Samples were boiled and analyzed on 12% 
polyacrylamide gels by SDS-PAGE and Western blot analysis for phosphorylated 
PKR as described above.  
Northern Blot Analysis.  BSC40 cells were mock-infected or infected 
with VACV, VACV-E3L∆37N, or MPXV at a MOI of 5.  Total RNA was 
isolated using the RNeasy Mini Kit (Qiagen), according to manufacturer’s 
instructions. Total RNA (1.5 μg) was separated by electrophoresis in 1% agarose 
formaldehyde gels according to manufacturer’s instruction (Northern Max kit, 
Ambion). Seperated RNA was transferred to positively charged BrightStar-Plus 
Membrane (Ambion) and the membrane was UV crosslinked using the Stratagene 
Stratalinker 1800.  The A10L riboprobe was synthesized by in vitro transcription 
using PCR products generated from a VACV DNA template via primer pair 
A10L-T7 (5’- CTA ATA CGA CTC ACT ATA GGG AGA GTC TAG CAG 
CAT CTG CGA TG - 3’) and A10L-R (5’- CAA CCT TCG TTC ATC CGT TC - 
3’). The forward primer contained a T7 RNA polymerase promoter-recognition 
sequence (underlined).  Digoxigenin (DIG)-labeled riboprobe was obtained by in 
vitro transcription with T7 RNA polymerase according to manufacturer’s 
instructions (DIG RNA labeling kit, Roche Diagnostics). Hybridization was 
carried out at 68°C with 100 ng/mL of DIG labeled riboprobe according to 
manufacturer’s instructions (Northern Max kit, Ambion).  DIG signal detection 
was performed according to manufacturer’s instructions (DIG Luminescent 
Detection Kit, Roche Diagnostics).    
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RESULTS 
 
MPXV produces a truncated version of the VACV E3L protein.  To 
begin to understand how MPXV is able to inhibit the IFN anti-viral immune 
response.  We first wanted to identify the size of the F3L protein produced by 
MPXV and confirm the F3L gene sequence coded for a truncated version of the 
protein.  Based on a ClustalW alignment between the F3L protein of MPXV and 
the E3L proteins of VACV and VARV, the C-terminal dsRNA BD is highly 
conserved between all three proteins, whereas the N-terminus is far less conserved 
for the MPXV F3L protein, resulting in a protein truncated of the first 37 amino 
acids (Fig. 4). To determine if the MPXV F3L protein is truncated as compared to 
the VACV E3L protein, HeLa cells were infected with VACV, VACV-E3L∆37N, 
and MPXV at a MOI of 5 and protein lysates were harvest at 6 hpi.  Western blot 
analysis with antiserum towards the VACV E3L protein shows that VACV 
produces both the p25 and p20 forms of E3L, while VACV-E3L∆37N generated 
only the p20 form of E3L (Fig. 5).  In contrast, MPXV produced a protein that is 
similar in size to the protein produced by VACV-E3L∆37N, a virus known to 
produce a protein deleted of the first 37 amino acids.  These results confirm that 
MPXV produces a truncated version of the VACV E3L homologue and that the 
F3L protein is deleted of the first 37 amino acids from the N-terminus, confirming 
the sequence alignment.  In addition, these results confirm that VACV E3L 
antibodies recognize the MPXV F3L protein. 
MPXV possesses an IFN Resistant Phenotype.  To determine if MPXV 
is able to inhibit the IFN anti-viral immune response and replicate in the presence 
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of IFN, we treated RK-13 cells with increasing amounts of IFN-α A/D (0 – 1,000 
U/mL) for 18 hours.  After IFN treatment, the cells were infected with 100 PFU 
of MPXV and 48 hours later the plaques were stained with crystal violet.  MPXV 
plaque formation was unaffected by IFN treatment, since that the number of 
MPXV plaques remained the same as the concentration of IFN increased (Fig. 
6A).   
To further confirm the IFNR phenotype of MPXV, we performed single-
step growth kinetics in Vero-E6 and HeLa cells in the presence of absence of IFN.  
Vero-E6 and HeLa cells were pretreated with 1000 U/mL of IFN-α A/D and 
infected with VACV, VACV-E3L∆37N, and MPXV.  At 24 hpi the cells were 
harvested and viral titers were determined.  MPXV replication was unaffected by 
IFN pretreatment, since the viral titers were similar in the presence of absence of 
IFN (Fig. 6B).  VACV and VACV-E3L∆37N also replicated to high titers in the 
presence of IFN (data not shown).  These data suggest that MPXV possesses an 
IFNR phenotype similar to that of VACV and VACV-E3L∆37N. 
MPXV prevents phosphorylation of PKR and eIF2α.  The VACV E3L 
protein inhibits the IFN anti-viral immune response by preventing the 
phosphorylation of PKR and eIF2α (30).  To determine is MPXV inhibits the 
response by a similar mechanism we wanted to analyze the levels of 
phosphorylated PKR and eIF2α present during a MPXV infection.  Additionally, 
we wanted to compare the levels of PKR and eIF2α phosphorylation in MPXV, 
VACV and VACV-E3L∆37N infected cells since VACV-E3L∆37N was shown 
previously to induce activation of the PKR pathway at late times post infection in 
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HeLa cells (75), To begin to uncover the MPXV IFNR phenotype, HeLa cells 
were either mock-infected or infected with VACV, VACV-E3L∆37N, 
VACV∆E3L, or MPXV in the presence of absence of IFN.  Protein lysates were 
harvested at 6 and 9 hpi and analyzed by western blot with antiserum towards the 
phosphorylated forms of PKR and eIF2α.  In addition, antiserum towards GAPDH 
was used to ensure equal loading of samples.  Mock-infected and VACV infected 
cells show undetectable levels of phosphorylated PKR and eIF2α (Fig. 7).  In 
contrast, VACV∆E3L infected cells show high levels of phosphorylated PKR and 
eIF2α at both 6 and 9 hpi. VACV-E3L∆37N caused the phosphorylation of PKR 
and eIF2α at 9 hpi, but not 6 hpi, corresponding to the late activation of the PKR 
pathway as previously described (75).  Most notably, MPXV did not cause the 
phosphorylation of PKR and eIF2α at either time point regardless of IFN 
treatment.  Therefore, these data suggest that MPXV can inhibit the IFN anti-viral 
immune response more similar to VACV than VACV-E3L∆37N.   
MPXV replicates in JC cells.  JC cells represent one of two in vitro 
models for analyzing the N-terminus of the VACV E3L protein (Trainor and 
Jacobs, in preparation).  As stated previously, VACV containing N-terminal 
truncations in E3L (i.e. VACV-E3L∆37N and VACV-E3L∆83N) are unable to 
replicate in these cells (Trainor and Jacobs, in preparation).  Considering MPXV 
contains a natural N-terminal truncation in F3L, we hypothesize that this virus 
should not be able to replicate in these cells.  Therefore, we performed multi-step 
growth kinetics in JC cells comparing the replication of VACV, VACV-
E3L∆37N, and MPXV.  At 72 hpi, VACV replicated to high titers, whereas 
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VACV-E3L∆37N was unable to replicate in JC cells (Fig. 8).  Remarkably, 
MPXV was able to replicate to titers similar as VACV in these cells.  This 
suggests that either the amino acid changes present in the F3L protein may 
compensate for the loss of the N-terminal Z-NA-BD or the virus evolved an 
alternative mechanism(s) to counteract the host anti-viral immune response. 
MPXV F3L protein does not rescue the VACV-E3L∆37N phenotype 
in HeLa and JC cells.  To determine if the amino acid changes present in the 
MPXV F3L protein or perhaps another viral mechanism(s) is compensating for 
the loss of the N-terminal Z-NA-BD (Fig. 4), we generated a VACV that 
expresses the F3L protein of MPXV in the place of E3L (VACV∆E3L::F3L) (Fig. 
9).  We then asked if F3L could restore the IFNR phenotype of VACV∆E3L.  A 
plaque reduction assay in the presence of increasing amounts of IFN in RK-13 
cells shows that the F3L protein was able to restore the IFNR phenotype of a 
VACV originally deleted of the E3L protein (Fig. 9).  These data suggest that the 
MPXV F3L protein is sufficient for conferring the IFNR phenotype of MPXV.  To 
determine if the F3L protein could restore a fully wild-type phenotype to 
VACV∆E3L, we examined PKR and eIF2α phosphorylation at late times post 
infection in HeLa cells.  HeLa cells were infected with VACV, VACV-E3L∆37N, 
VACV∆E3L, and VACV∆E3L::F3L at a MOI of 5.  At 6 and 9 hpi protein lysates 
were obtained and analyzed by western blot for the phosphorylated form of PKR 
and eIF2α.  As demonstrated previously, no detectable levels of phosphorylated 
PKR or eIF2α were detected in VACV infected cells, whereas cells infected with 
VACV∆E3L show high levels of PKR and eIF2α phosphorylation at both 6 and 9 
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hpi (Fig. 10).  Cells infected with VACV-E3L∆37N show levels of PKR and 
eIF2α phosphorylation at only 9 hpi.  The cells infected with VACV∆E3L:F3L 
also show detectable levels of PKR and eIF2α phosphorylation at only 9 hpi, 
suggesting that the amino acid changes present in the F3L protein was not able to 
fully inhibit activation of PKR in a VACV background.   
We then asked if F3L protein of MPXV could restore VACV∆E3L 
replication of in the JC cells.  Multi-cycle growth kinetics were performed with 
VACV∆E3L:F3L in JC cells. Viral titers of VACV∆E3L:F3L were similar to 
those for VACV-E3L∆37N, suggesting that VACV∆E3L:F3L was unable to 
replicate in these cells (Fig. 11).   Therefore, the amino acid changes present in 
the F3L protein are not allowing for full inhibition of PKR and replication in JC 
cells.  Together these data suggest that an alternative viral mechanism(s) is 
compensating for the loss of the N-terminal Z-NA-BD, allowing for the wt-
VACV phenotype in HeLa cells and replication in JC cells.  
MPXV produces significantly less dsRNA than VACV in HeLa cells.  
We hypothesized that another viral mechanism is compensating for the loss of the 
N-terminus of F3L in MPXV.  Therefore, we decided to compare at the 
accumulation of dsRNA during a MPXV and VACV infection.  dsRNA 
accumulation in HeLa cells was determined by immunofluorescence with 
antibodies that specifically recognize dsRNA (107).   We co-stained cells for E3L, 
to ensure all the cells were infected.  At 3 hpi, E3L and F3L were detected in 
VACV, VACV-E3L∆37N, and MPXV infected cells, but no dsRNA was detected 
at this time (Fig. 12).  This was not unexpected considering the majority of 
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dsRNA generated during a VACV infection is produced during intermediate and 
late viral gene transcription and relatively few intermediate and late viral 
transcripts have accumulated by 3 hpi.  At 6 hpi, both E3L and dsRNA were 
detected in VACV and VACV-E3L∆37N infected cells (Fig. 13).  Punctate 
staining was observed for both E3L and dsRNA and the merge shows that E3L 
overlays with a significant portion of the dsRNA.  This suggests that E3L and the 
dsRNA may be interacting in the infected cells, most likely through E3L’s C-
terminal dsRNA-BD.  Remarkably, no dsRNA staining was observed in MPXV 
infected cells.  The lack of dsRNA accumulation in these cells was not due to a 
low level of MPXV infection since F3L was detected in all of the cells.  Infected 
HeLa cells stained at 9 hpi show high levels of dsRNA for both the VACV and 
VACV-E3L∆37N with E3L colocalizing with the dsRNA (Fig. 14). Furthermore, 
an accumulation of dsRNA was not observed in the MPXV infected cells at this 
time; however, F3L staining shows that all the cells were infected.  These data 
suggest that MPXV has a unique characteristic of generating low levels of dsRNA 
during an infection.  This characteristic may allow MPXV to overcome the F3L 
N-terminal truncation allowing the virus to prevent PKR activation and replicate 
in JC cells. 
To determine if MPXV is capable of generating dsRNA that is 
undetectable by immunofluorescence we examined the production intermediate 
and late viral transcripts, viral products known to produce the dsRNA during a 
VACV infection, by Real-Time quantitative PCR with primers specific for early 
(M1L), intermediate (G8R), and late (A5L) viral transcripts.  In VACV infected 
  45 
cells, a considerable increase of intermediate and late viral transcripts was 
detected by 4 hpi and their levels continued to increase throughout the infection 
(Fig. 15).  Prior to 4 hpi the levels of intermediate and late viral transcripts were 
relatively low, consistent with the immunofluorescence data at 3 hpi (Fig. 12).  
Considerable increases in MPXV intermediate and late viral transcripts were 
detected by 6 hpi and continued to increase throughout the infection (Fig. 15).  
These data suggest that MPXV viral transcription may be delayed by two hours as 
compared to VACV transcription.  However, this does not explain why no dsRNA 
was  not observed by immunofluorescence in the MPXV infected cells at both 6 
and 9 hpi (Fig. 13 and Fig. 14), as the levels of MPXV viral transcripts at 8 hpi 
were similar to those levels observed for VACV at 6 hpi.  To further confirm that 
MPXV was producing dsRNA, we analyzed when viral genome replication 
initiated for MPXV and VACV using Real-Time Quantitative PCR, since 
intermediate and late viral transcription occurs immediately following the 
initiation of genomic replication (62, 140-141).  Real-Time Quantitative PCR for 
viral genome replication initation was performed with the G8R gene specific 
primer set on DNA extracted from HeLa cells infected with VACV and MPXV.  
VACV genomic replication initiated around 2 hpi and increased considerably 
from 4 to 6 hpi (Fig. 16).  MPXV genomic replication initiated after 2 hpi and 
increased significantly from 6 to 10 hpi.  Ultimately, VACV and MPXV 
generated similar levels of viral genome by 10 hpi.  These data suggest that the 
MPXV life cycle maybe delayed by two hours in HeLa cells as compared to 
VACV.     
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Considering the delay in MPXV transcription and genomic replication, we 
looked for dsRNA accumulation by immunofluorescence at 12 hpi.  A much 
small amount of dsRNA in MPXV infected cells was observed as compared to 
VACV (data not shown). These data confirm that MPXV is capable of producing 
significant amounts of the viral transcripts known to form dsRNA; however, the 
amount of dsRNA generated during a MPXV seems to be significantly less than 
the amount generated during a VACV infection.   
To confirm MPXV was producing less dsRNA than VACV throughout the 
course of an infection, we employed several methods to specifically analyze the 
amount of dsRNA produced.  First we analyzed dsRNA levels by western blot 
analysis with antibodies specific for dsRNA.  HeLa cells were infected with 
VACV, VACV-E3L∆37N, and MPXV at a MOI of 5 and total RNA was isolated 
at 3, 6, 9 and 12 hpi.  VACV and VACV-E3L∆37N generated detectable amounts 
of dsRNA at 6 hpi and dsRNA levels continued to increase by 12 hpi (Fig. 17).  In 
contrast, MPXV dsRNA was not detected until 9 hpi and increased slightly by 12 
hpi; however, the total amount of dsRNA generated by MPXV appeared to be less 
than the levels observed for VACV and VACV-E3L∆37N.  To determine 
quantitatively that MPXV produces less dsRNA than VACV during an infection, 
we used an ELISA based assay with the J2 (IgG2a) anti-dsRNA antibody as the 
capture antibody and the K1 (IgM) anti-dsRNA antibody as the detection 
antibody.  Total RNA was extracted from HeLa cells infected with VACV and 
MPXV and added to an ELISA plate containing the capture antibody.  MPXV 
dsRNA levels were reduced on average by 40-50% as compared to VACV 
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between 6 and 12 hpi (Fig. 18).   We then performed an in vitro PKR assay to 
compare the amounts of dsRNA generated during a VACV and MPXV infection 
since there is a direct relationship between the amounts of dsRNA and 
phosphorylated PKR present within a sample.  For this assay, RNA was isolated 
at 1, 6 and 12 hpi from mock, VACV, and MPXV infected cells.  Isolated RNA 
was incubated with cytoplasmic extracts containing unphosphorylated PKR and 
ATP was added as the substrate for PKR.  The amount of phosphorylated PKR 
was determined by western blot with antibodies specific for the phosphorylated 
form of PKR and densities of each band were quantified with ImageQuant 4.1 
software.  Numerical values represent the relative band density as compared to the 
band produced by RNA isolated at 12 hpi from VACV infected cells, since it 
resulted in the highest amount of phosphorylated PKR (Fig. 19).   At 6 hpi, 
VACV induced PKR phosphorylation, but to a level five times less than at 12 hpi.  
The RNA isolated from mock-infected cells at 1, 6, and 12 hpi did induce PKR 
phosphorylation, but to a level 20 times less than VACV at 12 hpi.  At 1 and 6 hpi 
the levels of phosphorylated PKR observed for MPXV were similar to levels seen 
for mock-infected cells.  At 12 hpi, MPXV RNA induced PKR phosphorylation, 
but to a level that was about three times less than the levels for VACV at 12 hpi.  
Therefore, these data confirm that in HeLa cells MPXV produces significantly 
less dsRNA than VACV during the course of an infection.   
MPXV produces less dsRNA than VACV in JC cells.  Producing less 
dsRNA in HeLa cells may offer one explanation as to why MPXV was able to 
successful replicate in JC cells, whereas the replication of VACV-E3L∆37N was 
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inhibited.  To begin to compare the dsRNA levels produced during a MPXV and 
VACV infection in JC cells, we first wanted to see if MPXV transcription and 
genomic replication was delayed in these cells and to determine optimal times to 
compare dsRNA levels by immunofluorescence.  Therefore, we performed Real-
Time Quantitative PCR for viral transcripts with gene specific primers for the 
M1L, G8R, and A5L genes, from RNA extracted from JC cells infected with 
VACV, MPXV, and VACV-E3L∆37N at 1, 2, 4, 6, 8, 10, and 12 hpi.  In VACV 
infected cells at 2 hpi, viral transcripts were induced by 10 fold and continued to 
increase to over a 1,000 fold for the intermediate and late genes by 12 hpi (Fig. 
20).  In the cells infected with VACV-E3L∆37N, all three genes were induced 2 
hpi, but failed to induce transcripts to levels comparable to VACV at later times 
post infection (Fig. 20), correlating with the inability of VACV-E3L∆37N to 
replicate to wild-type titers within these cells (Fig. 8).  MPXV early and late viral 
transcripts were induced to similar levels as VACV at all time points; however, 
intermediate viral transcripts were 10 fold higher in VACV infected cells at late 
times post infection (Fig. 20).  In addition, we preformed Real-Time Quantitative 
PCR to measure viral genomic replication initiation using the G8R primer set.  
Similar to the viral G8R transcription initiation, VACVgenomic replication 
initiated at around 2 hpi and continued to increase until 12 hpi (Fig. 21).  The two 
hour lag in MPXV viral transcription and genomic replication observed in the 
HeLa cells was not as apparent in the JC cells.  Based on these data, we 
hypothesized that dsRNA levels should be similar between VACV and MPXV at 
6 and 9 hpi.  Therefore, we performed immunofluorescence with dsRNA specific 
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antibodies on VACV and MPXV infected JC cells at 6 and 9 hpi.  By 6 hpi 
dsRNA was detected in the VACV infected cells, whereas dsRNA was 
undetectable at both 6 and 9 hpi in the MPXV infected cells (Fig. 22).  Therefore, 
MPXV appears to be making less dsRNA in the JC cells, similar to what was 
previously observed in HeLa cells (Fig. 12-14).     
MPXV is resistant to the anti-poxvirus drug IBT.  The anti-poxvirus 
drug IBT has been shown to increase the amount of dsRNA present during an 
infection by inducing longer than normal intermediate and late viral transcripts 
(97).  Given that effects of IBT have been mainly characterized in BSC-40 cells, 
we choose to use these cells to determine MPXV’s IBT phenotype. This increase 
in transcript length results in an increase in dsRNA.  IBTR mutants of VACV 
accumulate less dsRNA than wt-VACV and it is suspected this is due to the 
generation of shorter intermediate and late transcripts both in the presence and 
absence of IBT (10). Since MPXV appears to be producing less dsRNA than 
VACV, we hypothesized that MPXV maybe naturally resistant to IBT leading to 
the reduced accumulation of dsRNA observed in MPXV infected cells.  We first 
used a plaque reduction assay with increasing amounts of IBT to determine if 
MPXV was susceptible to IBT.  At a concentration of 7.5 µM the number of 
VACV plaques was reduced by ~ 50%, and at a concentration of 30 µM, VACV 
plaque formation was completely inhibited (Fig. 23).  A 50% plaque reduction in 
MPXV plaques was observed at a concentration 60 µM and a complete reduction 
of MPXV plaques required 120 µM of IBT.  Thus, MPXV is 8-fold more resistant 
to IBT than VACV.  In addition, we also compared the plaquing efficiency of 
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MPXV in the presence of increasing amounts of IBT to a known IBTR (IBT 
resistant) virus (VACV-A24R-R1, kindly provided by Dr. Rich Condit).   VACV-
A24R-R1 plaquing was only marginally affected at the highest dose of IBT (120 
µM), suggesting that MPXV has an intermediate IBTR phenotype than VACV-
A24-R1.  To further confirm the IBTR phenotype on MPXV, we performed multi-
step growth kinetics with VACV, MPXV, and VACV-A24R-R1 in BSC-40 cells 
in the presence of 60 µM IBT.  In the absence of IBT, VACV, MPXV, and 
VACV-A24R-R1 replicated to similar titers; however, in the presence of IBT 
VACV replication was reduced by two logs whereas MPXV and VACV-A24R-
R1 replication was relatively unaffected (Fig. 24).  Therefore, together, these 
results confirm that MPXV has an IBTR phenotype. 
MPXV generates shorter viral transcripts than VACV.  The generation 
of shorter intermediate and late viral transcripts has been shown to lead to an 
IBTR phenotype for VACV (97).  This transcriptional phenotype may offer one 
explanation as to why MPXV possesses an IBTR phenotype and produces less 
dsRNA.  To compare the lengths of late viral transcripts generated by VACV and 
MPXV we utilized a northern blot with a specific for the late VACV A10L 
transcript.  RNA was extracted from IBT-treated (30µM) or untreated BSC-40 
cells infected with VACV, MPXV, and VACV-A24R-R1 at 9 hpi.  In the absence 
of IBT, VACV generated A10L transcripts with an average size of 7,300 base 
pairs (bps), whereas MPXV and A24R-R1 generated much smaller transcripts 
with an average size of 3200 and 3400, respectively (Fig. 25).  VACV infected 
cells treated with IBT show RNA degradation of the A10L transcript,  most likely 
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through the activation of the 2’5’ OAS pathway (34).  In contrast, VACV-A24R-
R1 and MPXV RNA was intact following IBT treatment and in accordance with 
the known affects of IBT, the RNA was longer than normal with an average size 
of about 9,300 bps and 6,700 bps, respectively (Fig. 25).  Therefore, these data 
suggest that the IBTR phenotype of MPXV may be linked to the production of 
smaller than normal transcripts, thereby causing a reduction in accumulation of 
viral dsRNA.  This reduction in viral dsRNA, by generating shorter viral 
transcripts, may allow MPXV to overcome the N-terminal truncation observed in 
F3L. 
Given that IBT treatment caused an increase in MPXV RNA, similar to 
the size seen for VACV in the absence of IBT, we hypothesized that this increase 
in MPXV transcript size could lead to an increase in dsRNA levels, thereby 
inducing PKR phosphorylation and allowing for dsRNA detection by 
immunofluorescence in MPXV infected HeLa cells.  Western blot analysis on 
protein lysates isolated at 9 hpi from VACV, MPXV and VACV-A24R-R1 
infected HeLa cells treated with increasing amounts of IBT show an increase in 
phosphorylated PKR for all three viruses (Fig. 26).  Phosphorylated PKR was not 
detected for VACV, MPXV, and VACV-A24R-R1 in untreated cells, but at the 
lowest concentration (7.5 µM) high levels of phosphorylated PKR was observed 
for VACV.  High levels of phosphorylated PKR were detected at IBT 
concentrations of 30 µM and 120 µM of IBT for MPXV and VACV-A24R-R1, 
respectively.  Immunofluorescence analysis with antibodies specific for dsRNA 
confirm this increase in detectable levels of dsRNA in IBT treated MPXV 
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infected HeLa cells (Fig. 27).  In the presence of 30 µM IBT, dsRNA was 
detected in MPXV infected cells at 9 hpi, whereas MPXV dsRNA was 
undetectable in the absence of IBT.  Similar to VACV at 9 hpi (Fig. 14), punctate 
staining of F3L suggests the protein is co-localized with the dsRNA present when 
IBT treatment increased dsRNA levels in these cells (Fig. 27, merge).  Together, 
these data suggest the MPXV F3L protein may prevent binding of the dsRNA 
antibodies to the dsRNA due to their short size in the absence of IBT; however 
following IBT treatment, F3L can no longer prevent the binding of the antibodies 
to the longer dsRNAs.  Additionally, these data may suggest MPXV evolved a 
mechanism(s) to generate shorter dsRNAs to compensate for the loss of the N-
terminus of F3L and allow for full inhibition the host’s antiviral immune 
response. 
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DISCUSSION 
 
  MPXV is capable of causing a severe smallpox-like disease in humans 
and following the eradication of smallpox in 1977, it has become the most 
problematic virus within the genus Orthopoxvirus in regards to human health 
(21).  Therefore, to begin to understand the disease associated with a MPXV 
infection, we must first gain a better understanding of how MPXV subverts the 
host’s anti-viral immune response and cause disease in humans.  The majority of 
all known viruses have evolved ways to inhibit a host’s ability to defend against a 
viral infection.  For Orthopoxviruses, two proteins in particular, E3L and K3L, are 
known to play an important roles in preventing activation of host’s anti-viral 
immune response associated viral dsRNA (11-13, 26, 29-30, 137). 
 Sequence analysis of the MPXV genome suggested that MPXV expresses 
an ortholog of the VACV-E3L protein, F3L, but not a functional K3L protein.  
However, based on the MPXV F3L nucleotide sequence, it was believed that the 
F3L protein contained a deletion of the first 37 amino acids from the N-terminus.  
It has been well established for the VACV that a full-length E3L protein is 
required for viral host range, wild-type pathogenesis in vivo, and full IFNR in vitro 
(20, 76) (White and Jacobs, submitted).  It is unclear whether the combination of 
the N-terminal truncation of F3L and inability to generate a functional K3L 
protein would permit MPXV to possess an IFNR and host range phenotype similar 
to VACV.  Therefore, we asked if MPXV was able to inhibit the IFN anti-viral 
immune response as efficiently as VACV or VACV-E3L∆37N.   
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 We initially wanted to determine if the gene encoding for the MPXV F3L 
protein did produce a truncated version of the VACV E3L protein.  The VACV-
E3L gene encodes for both a full length version of E3L (p25) and a truncated 
version, deleted of the first 37 amino acids from the N-terminus (p20) (30, 144).  
Western blot analysis with antibodies specific for the VACV-E3L protein 
confirmed that MPXV did indeed produce only one version of the F3L protein 
and that protein was similar in size to the truncated p20 version of E3L expressed 
by VACV-E3L∆37N.  Based on the F3L gene sequence, a frameshift and minor 
deletions in the N-terminal coding region resulted in the mutation of the first 
AUG start codon and translation initiation at a second downstream AUG creating 
a protein deleted of the first 37 amino acids from the N-terminus.     
 Both N-terminal and C-terminal domains of the VACV E3L protein have 
been shown to be necessary for the complete inhibition of the PKR pathway (75) 
and wild-type pathogenesis within an animal model (19).  Previously, in vitro 
studies showed that VACV-E3L∆83N and VACV-E3L∆37N have a host range 
and IFNR phenotype similar to wt-VACV (29, 113).  Since MPXV expresses an 
E3L homologue similar to the protein expresses by VACV-E3L∆37N, this 
suggested that MPXV should have a phenotype more similar to VACV-E3L∆37N 
and not wt-VACV.  To determine if the truncated F3L protein of MPXV prevents 
the virus from inhibiting the anti-viral immune response as efficiently as wt-
VACV, we initially explored MPXV’s ability to plaque and replicate in the 
presence of IFN.  As previously mentioned, IFN can cause an induction of various 
ISGs that are capable of inducing an anti-viral state in a cell and prevent viral 
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replication (18).  IFN treatment did not affect MPXV plaque formation or 
replication in the RK-13, Vero-E6 and HeLa cells.  This was not unexpected since 
VACV-E3L∆37N has been shown to plaque and replicate to high levels following 
IFN treatment (114).  These data suggest that MPXV possesses an IFRR 
phenotype that is similar to VACV and VACV-E3L∆37N.   
 As shown previously, VACVs expressing an N-terminal mutants of E3L, 
in vitro, induce PKR phosphorylation at late times post infection in HeLa cells 
(75).  Since MPXV contains an equivalent E3L N-terminal truncation as VACV-
E3L∆37N and VACV-E3L∆37 is known to lead to high levels of PKR 
phosphorylation at late times post infection in HeLa cells, we investigated how 
effective MPXV was at preventing the phosphorylation and activation of PKR.  
MPXV inhibited PKR phosphorylation more similar to VACV than VACV-
E3L∆37N.  VACV-E3L∆37N induced PKR phosphorylation by 9 hpi, while PKR 
phosphorylation was undetectable in MPXV infected cells at the same time. This 
suggests that MPXV is more effective than VACV-E3L∆37N at preventing 
activation of the anti-viral immune response, especially the PKR pathway.   
 Previously, the only methods for analyzing the function of the E3L N-
terminus were to perform in vivo pathogenesis studies and look for late activation 
of PKR in vitro. However, recently the JC murine mammary adenocarcinoma cell 
line has given us the ability to further characterize the function of the N-terminal 
Z-NA-BD of E3L.  In this cell line VACV replication was linked to the ability of 
E3L to bind to Z-DNA (Trainor and Jacobs, in preparation).  Any mutation 
(truncation or single amino acid point mutations) that affected E3L binding to Z-
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DNA prevented replication in these cells.  Furthermore, the ability of VACV E3L 
N-terminal mutants to replicate in JC cells correlates with pathogenesis in a 
mouse model.  Analogous to the replication data, any mutation that affected Z-
DNA binding decreased the ability of the virus to cause pathogenesis in a mouse 
model.  Since MPXV is missing the first 37 amino acids from the N-terminus and 
its IFNR phenotype more resembled wt-VACV than VACV-E3L∆37N, we then 
wanted to determine if MPXV was able to replicate in the JC cells.  Theoretically, 
MPXV should not be able to replicate in the JC cells due to the F3L N-terminal 
truncation; however, MPXV was able to replicate to high titers within these cells.  
These data suggest that MPXV may have evolved another mechanism to 
compensate for the partial loss of the N-terminus and completely inhibit the anti-
viral immune response similar to wt-VACV.   
 To begin to test this hypothesis, an analysis of the MPXV-F3L protein 
sequence revealed that F3L may have a stronger affinity of Z-DNA than the 
VACV E3L protein.  The VACV E3L protein has 7 out of the 9 conserved amino 
acids known to make contact and increase affinity for Z-DNA (67), while the 
MPXV F3L protein contains 8 conserved residues.  The MPXV F3L protein 
contains a threonine at position 62 instead of the isoleucine present in the VACV-
E3L protein.  Since the threonine is conserved among many other Z-DNA binding 
proteins (67), the MPXV F3L protein could have a stronger affinity for Z-DNA.  
Given that replication in JC cells correlated with Z-DNA binding, this could 
explain why MPXV was able to replicate in JC cells.  To test this hypothesis, we 
generated a recombinant VACV that expressed the MPXV F3L protein, 
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VACV∆E3L::F3L.  We first confirmed that the MPXV-F3L protein was able to 
restore the IFNR phenotype of VACV∆E3L.  Therefore, this suggested that the 
MPXV F3L protein is an IFNR antagonist that plays a major role in MPXV 
inhibition of the host’s anti-viral immune response.  If the mutations present in 
F3L are allowing for an increased binding affinity for Z-DNA, then 
VACV∆E3L:F3L should replicate to levels similar as MPXV in JC cells.  
However, under multi-cycle conditions VACV∆E3L:F3L was unable to replicate 
in the JC cells.  In accordance with VACV∆E3L:F3L inability to replicate in JC 
cells, this virus was also not able to rescue the E3L N-terminal phenotype in HeLa 
cells.  At late times post infection VACV∆E3L:F3L induced the phosphorylation 
and activation of PKR comparable to VACV-E3L∆37N at 9 hpi.  These results 
suggest the amino acid changes present in the MPXV F3L protein are not 
responsible for MPXV replication in JC cells and to compensate for the loss of the 
N-terminus, the virus has evolved another mechanism allowing MPXV to have a 
phenotype more similar to VACV than VACV-E3L∆37N.  Further experiments to 
determine the Z-DNA binding affinity of F3L could provide us with valuable 
information that could help in gaining a better understanding of the function 
related to the E3L N-terminus.  As previously shown, Z-DNA was directly related 
with VACV replication of in JC cells (Trainor and Jacobs, in preparation) and if 
F3L has stronger affinity for Z-DNA than E3L, then this would go suggest the N-
terminus of E3L may play another role in preventing activation of the host’s 
antiviral immune response independent of Z-DNA binding. 
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 Host cells have evolved multiple mechanisms to detect a viral infection 
through systems designed to recognize a byproduct of viral replication, dsRNA 
(4, 59, 63, 99, 104, 127).  As such, the majority of all known viruses have evolved 
multiple strategies to prevent the activation of those systems.  For example, 
VACV uses the E3L protein to sequester the dsRNA and hide it from the host’s 
PRRs (i.e. TLR3, RIG-I, MDA-5, PKR) responsible for activating the anti-viral 
immune response associated with dsRNA (30, 137, 144).  In addition to using 
viral proteins to directly block the activation of those PRRs, it is also possible a 
virus might evolve a mechanism to limit the amount of dsRNA produced during 
an infection.  This could offer a selective advantage to the virus, allowing the 
virus to replicate in the cells without triggering the activation of the anti-viral 
immune response.  To answer the question as to why MPXV was able to replicate 
in the JC cells and prevent the activation of PKR at late times in HeLa cells, we 
decided to compare dsRNA levels produced during a VACV and MPXV 
infection.  Through immunofluorescence with antibodies specific for dsRNA, we 
show that MPXV generated lower levels of dsRNA as compared to VACV. 
During a VACV and VACV-E3L∆37N infection high levels of dsRNA were 
produced at both 6 and 9 hpi and in the MPXV infected cells dsRNA was 
undetectable at a similar time point.  This suggests that MPXV may be producing 
less dsRNA than VACV and this may explain the MPXV phenotypes in the JC 
and HeLa cells. To ensure the lower levels of dsRNA were not due to an inability 
of MPXV to infect and replicate as efficiently in HeLa cells as VACV, we 
performed Quantitative Real-time PCR for early, intermediate and late viral 
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transcripts.  Since intermediate and late viral transcripts are known to form the 
majority of dsRNA produced during a VACV infection (57), we compared the 
levels of those genes and determined that there was no substantial difference 
between MPXV and VACV, with the exception that MPXV transcription 
appeared to be delayed by two hours.  However, this delay not explain why we 
were unable to detect any dsRNA at 9 hpi, since the levels of MPXV transcripts at 
8 hpi were similar to levels seen for VACV at 6 hpi and dsRNA was observed for 
VACV at 6.  To confirm the delay in transcription was not affecting our ability to 
detect the dsRNA in the MPXV infected cells, we also looked at MPXV and 
VACV infected cells at 12, 15, and18 hpi by immunofluorescence. Extremely low 
levels of dsRNA were present in the MPXV infected cells, but they did not 
increase much past 12 hpi and were considerably less than was observed for the 
VACV infected cells (data not shown).   
 Given that lower levels of dsRNA were detected in MPXV infected cells 
by immunofluorescence, we wanted to quantitatively compare the levels of 
dsRNA generated during a MPXV and VACV infection.  The most widely 
accepted method for quantitating dsRNA in the past was to use tritiated uridine, 
but working with radioactivity in the BSL-3 is extremely difficult.  Instead, we 
performed one qualitative and two quantitative assays to compare the levels of 
dsRNA generated between VACV and MPXV.  In all three assays, MXPV 
consistently produced less dsRNA than VACV.  Based on the ELISA and in vitro 
PKR assay, MPXV generated anywhere from two to three fold less dsRNA than 
VACV, respectively.  Producing less dsRNA could be advantageous to a virus 
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since, the virus would be able to replicate in the cells without activating the anti-
viral response.  MPXV may have evolved a way to make dsRNA as a method to 
compensate for the loss of the N-terminus.  This could suggest that the N-
terminus of E3L may play a role in sequestering the higher amounts of dsRNAs 
present during a VACV infection.  Additionally, this may explain why VACV-
E3L∆37N is not able to prevent PKR phosphorylation at late times post infection 
in HeLa cells, unlike wt-VACV.       
 To confirm MPXV possesses a similar low level dsRNA phenotype in the 
JC cells, we first performed Quantitative Real-time PCR for MPXV and VACV 
viral transcripts to determine the optimal time to look for the presence of dsRNA 
by immunofluorescence.  We did not detect any considerable difference in 
intermediate and late gene induction between MPXV and VACV, similar to the 
HeLa cells.  However, the two hour delay in transcription of the MPXV versus the 
VACV genes was not as pronounced in the JC cells.  At 2 and 4 hpi, MPXV 
transcript levels were lower than VACV, but by 6 hpi the levels of the A5L gene 
were similar between the two viruses and remained similar throughout the 
duration of the experiment.  This was not the case in the HeLa cells, as MPXV 
A5L gene levels were always two hours behind the levels seen for VACV.  The 
mostly likely explanation for the differences in MPXV transcription rates between 
the JC and HeLa cells may be that MPXV more suited to replicate in mouse cells 
since MPXV is thought to be maintained in wild rodent populations in Central 
and West Africa and humans are an incidental host (64).  To compare the levels of 
dsRNA in MPXV and VACV infected JC cells we performed 
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immunofluorescence at 6 and 9 hpi, since viral transcripts were similar between 
MPXV and VACV at these times.  dsRNA was detected by 6 hpi for VACV, but 
in the MPXV infected cells at both 6 and 9 hpi, dsRNA was undetectable.  These 
data are consistent with the results obtained from the HeLa cells and confirm that 
MPXV is generating less dsRNA than VACV.   
Quantitatively we were able to show that MPXV produces dsRNA, but we 
were undetectable by immunofluorescence.   It is possible that the dsRNA 
antibodies may not have been able to bind to the dsRNA generated during a 
MPXV infection, due to the binding of F3L.  The antibodies were designed to 
recognize the alpha-helical structure of dsRNA (107), but if F3L completely cover 
the dsRNA epitope recognized by the antibodies, than we may not see the dsRNA 
by immunofluorescence.  We hypothesized that maybe MPXV producing less 
dsRNA by generating shorter viral transcripts since this would explain why we 
are not detecting the dsRNA by immunofluorescence.  If the dsRNA lengths 
produced during a MPXV are shorter it is possible the F3L protein completely 
sequesters the dsRNA and prevents binding of the dsRNA antibodies.  In contrast, 
the longer dsRNAs observed during a VACV infection may not be completely 
covered by E3L, thereby allowing the dsRNA antibodies to bind to the dsRNA.  It 
has been previously theorized that VACV IBTR could result from either the 
production of shorter viral intermediate and late viral transcripts or by developing 
a mutation that prevented drug binding (34, 97).  IBT increases read-through 
transcription producing longer than normal intermediate and late viral transcripts, 
which consequently increases viral dsRNA levels in the cell (97).  If our theory 
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that MPXV is generating shorter viral transcripts is true, then MPXV should be 
more resistant to IBT than VACV.  By looking at VACV, MPXV, and VACV-
A24R-R1 (IBTR) plaque reduction in the presence of increasing amounts of IBT, 
we show that MPXV is 5 to 6 times more resistant to IBT than VACV.  VACV-
A24R-R1 was more resistant to IBT than MPXV and we believe one possible 
explanation for this may be that VACV-A24R-R1 expresses a full length version 
of E3L and K3L, thereby allowing for better sequestration of the dsRNA and 
inhibition of PKR activation.  We further confirmed the IBTR phenotype of 
MPXV by looking at the ability of the virus to replicate in the presence of IBT.  
VACV replication was reduced by 2 log10 in the presence of IBT, while MPXV 
replicated to comparable levels in the presence or absence of IBT, similar as the 
IBTR VACV-A24-1R.  These data suggested that MPXV could be producing 
shorter viral transcripts.   
To determine if MPXV was generating shorter transcripts we performed 
Northern blot analysis with a probe specific for the A10L late viral transcript.  We 
successfully showed that A10L transcripts generated by MPXV were about half 
the size of the transcripts seen for VACV.  In addition, the transcript lengths for 
MPXV were similar in size to the transcripts generated by the known IBTR 
VACV-A24R-R1.  Furthermore, the Northern blot analysis added additional 
evidence to support MPXV’s IBTR phenotype since the RNA for both MPXV and 
VACV-A24R-R1 showed an increase their average size in the presence of IBT, 
while VACV RNA was completely degraded.  It is known that the IBTS 
  63 
phenotype of VACV is related to the activation of the 2’5’ OAS leading to the 
RNA degradation and an inhibition of viral replication (34).   
If MPXV is generating shorter dsRNAs and F3L is preventing the binding 
of dsRNA antibodies, could IBT treatment of MPXV infected cells allow for 
visualization of the dsRNA by immunofluorescence?  Since the Northern blot 
showed that IBT increased MPXV viral transcripts lengths to a size similar to that 
of VACV in the absence of IBT, we suspected this may allow for the detection of 
MPXV dsRNA by immunofluorescence.  Following IBT treatment of the MPXV 
infected cells we observed detectable levels of MPXV dsRNA only in the 
presence of IBT, conversely no dsRNA was detected in the absence of IBT.  
Additionally, we also noticed that F3L overlaid perfectly with the dsRNA, similar 
to what we observed in the VACV infected cells for E3L.   
Further experiments to better characterize the IBTR phenotype of MPXV 
may help gain insight into how MPXV evolved to subverts the host’s anti-viral 
immune response.  The exact mechanism of how IBT affects elongation and 
termination of transcription is unknown, but numerous VACV proteins have been 
shown to play roles conferring IBT resistance in VACV (i.e. A24R, J6R, G2R, 
J3R and H5R) (37-38).  All the VACV IBTR mutants discovered so far have 
contained a mutation(s) in one of these five genes that affect viral transcription 
and elongation.  MPXV does not contain similar mutations in any of the VACV 
IBTR genes, so characterizing the determinants of the MPXV  IBTR phenotype 
may help explain these observations.  By inserting fragments of the MPXV 
genome into VACV and looking for a rescue of replication in the presence of IBT 
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would aid in determining what MPXV protein is coding for IBTR.  The IBTR gene 
of MPXV could be one of the genes already identified in VACV or it could be in 
a yet unidentified gene, since MPXV IBTR evolved naturally and not selected for 
in the presence of IBT, as it was for all the VACV IBTR mutants.  Once the 
MPXV gene has been identified, it would be interesting to see if the gene could 
decrease dsRNA levels and transcripts sizes for VACV-E3L∆37N and restore 
replication in JC cells and prevent the activation of PKR at late times post 
infection in HeLa cells.  This would confirm our theory that MPXV replication in 
JC cells and the inhibition of PKR phosphorylation at late times post infection in 
HeLa cells is related to the lower levels of dsRNA produced during a MPXV 
infection, which results from the shorter viral transcripts generated during a 
MPXV infection.   
The ability of MPXV to generate shorter viral transcripts than VACV and 
produce less dsRNA may be the mechanism by which MPXV compensates for the 
loss of the K3L protein and the partial loss of the N-terminal Z-NA-BD of F3L.  
Another member of the family Poxviridae, Myxoma virus (MYXV), expresses a 
version of the VACV E3L protein that is deleted of the first 75 amino acids from 
the N-terminus (24).  We were able to show that this virus is resistant to the 
effects of IBT, as this virus formed plaques in the presence of 120 µM IBT (data 
not shown).  Currently, it is unknown if MYXV produces shorter viral transcripts 
and less dsRNA than VACV.  If MYXV also generates shorter viral transcripts 
and produces less dsRNA, this suggests that during the evolution of MPXV and 
MYXV a truncation in their respective VACV E3L homologues selected for the 
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ability to produced less dsRNA, to compensate for the loss of the N-terminal Z-
NA-BD.  Conversely, it is also possible that the ability to produce shorter 
transcripts and generate less dsRNA arose first and the truncation in their E3L 
homologues were never selected against.   
We believed this research has provided us with a greater understanding of 
how MPXV subverts the host’s anti-viral immune response and how the virus 
may have compensated for the partial loss of the N-terminal Z-NA-BD of F3L.  
Ideally, this research will provide us with a better platform to design vaccines 
and/or antivirals that would be effective in preventing against a MPXV infection.      
 
  
  
 
    
 
 
 
 
       
  
Fig. 4.  VACV-E3L homologue alignment.  ClustalW alignment of the 
Vaccinia Virus (VACV) E3L gene homologues comparing VACV , Variola 
virus (VARV) and Monkeypox virus (MPXV). The C-terminal dsRNA BD is 
highly conserved between all three viruses.  The N-terminal Z-NA BD for 
VACV and VARV is highly conserved, whereas the E3L homologue of MPXV 
(F3L) is predicted to contain a 37 amino acid N-terminal truncation. Amino 
acids highlighted in green show changes in sequences between MPXV, VARV 
and VACV. 
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Fig. 5.  MPXV produces a p20 from of VACV-E3L. HeLa 
cells were infected with VACV, VACV-E3L∆37N and MPXV at a 
MOI of 5.  At 6 hpi, protein lysates were isolated and analyzed by 
western blot analysis with antibodies specific for the C-terminus of 
E3L.   
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Fig. 6.  MPXV replication in the presence of IFN.  (A) RK-13 cells 
were treated with increasing amounts of IFN-α A/D for 18 hrs and then infected 
with 100 PFU of MPXV.  Cells were stained at 48 hrs post infection with 
crystal violet. (B) Single-cycle growth kinetics of MPXV in Vero-E6 and HeLa 
cells in the presence (+) or absence (-) of 1,000 U/mL of IFN-α A/D.  Cells 
were infected at a MOI 5 with MPXV.  Infections were harvested at 0 and 24 
hpi and titered by plaque assay on RK-E3L cells.  Data presented are means 
with standard error of multiple experiments.   
 
 
  68 
 
 
 
 
Fi
g.
 7
.  
In
hi
bi
tio
n 
of
 P
K
R
 p
at
hw
ay
 b
y 
M
PX
V
.  
H
eL
a 
ce
lls
 w
er
e 
ei
th
er
 m
oc
k-
in
fe
ct
ed
 o
r 
in
fe
ct
ed
 w
ith
 V
A
C
V
, V
A
C
V
∆
E3
L,
 V
A
C
V
-E
3L
∆
37
N
 a
nd
 M
PX
V
 in
 th
e 
pr
es
en
ce
 (+
) o
r a
bs
en
ce
  
(-
) o
f 1
00
0 
U
/m
L 
of
 IF
N
 a
t a
 M
O
I o
f 5
. P
ro
te
in
 ly
sa
te
s w
er
e 
is
ol
at
ed
 a
t 6
 a
nd
 9
 h
pi
 a
nd
 a
na
ly
ze
d 
by
 w
es
te
rn
 b
lo
t a
na
ly
si
s w
ith
 a
nt
ib
od
ie
s s
pe
ci
fic
 to
 th
e 
ph
os
ph
or
yl
at
ed
 fo
rm
s o
f P
K
R
 a
nd
 e
IF
2α
.  
D
et
ec
tio
n 
of
 G
A
PD
H
 w
as
 u
se
d 
to
 e
ns
ur
e 
eq
ua
l l
oa
di
ng
 o
f p
ro
te
in
s. 
 
 
 
 
  
  69 
  
1.0E+03
1.0E+04
1.0E+05
1.0E+06
1.0E+07
1.0E+08
1.0E+09
VACV VACV-E3L∆37N MPXV
Ti
te
r 
(P
FU
/m
L
)
Fig. 8.  MPXV replication in JC cells. Multi-cycle growth kinetics were 
performed in JC cells infected at a MOI 0.01 with VACV, VACV-E3L∆37N, 
and MPXV.  Infections were harvested at 0 and 72 hpi and titered by plaque 
assay in RK-E3L cells. Data presented are means with standard error of 
multiple experiments. 
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Fig. 9.  MPXV F3L protein restores IFNR phenotype.  Through in vitro 
recombination, the F3L protein of MPXV was inserted into the E3L locus of 
VACV∆E3L, generating a recombinant VACV that expresses the MPXV F3L 
protein (VACV-∆E3L::F3L). RK-13 cells were treated with increasing amounts 
of IFN-α A/D for 18 hrs, prior to infection with 100 PFUs of VACV-
∆E3L::F3L. At 48 hpi, the cells were stained with crystal violet. 
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Fig. 10.  Late activation of the PKR pathway by VACV∆E3L::F3L.  
HeLa cells were either mock-infected or infected with VACV, 
VACV∆E3L, VACV-E3L∆37N and VACV∆E3L::F3L at a MOI of 5. 
Protein lysates were isolated at 6 and 9 hpi and analyzed by Western blot 
analysis with antibodies specific to the phosphorylated forms of PKR and 
eIF2α.      
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Fig. 11.  VACV∆E3L::F3L replication is inhibited in JC cells.  
Multi-cycle growth kinetics in JC cells infected at a MOI 0.01 with 
VACV, VACV-E3L∆37N, MPXV, and VACV∆E3::F3L. Viruses 
were harvested at 0 and 72 hpi and titered by plaque assay in RK-E3L 
cells.  Data presented are means with standard error of multiple 
experiments. 
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Fig. 12.  VACV and MPXV dsRNA levels in HeLa cells at 3 hpi.   
HeLa cells were infected at a MOI of 5 with VACV, VACV-E3L∆37N and 
MPXV.  At 3 hpi the cells were fixed with methanol and stained for the 
presence of E3L or F3L (green) and dsRNA (Red). Nuclei (blue) were 
stained with DAPI. Merge panels represent an overlay of all three images.  
Yellow indicates the colocalization of E3L or F3L and dsRNA. 
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Fig. 13.  VACV and MPXV dsRNA levels in HeLa cells at 6 hpi.   
HeLa cells were infected at a MOI of 5 with VACV, VACV-E3L∆37N and 
MPXV.  At 6 hpi the cells were fixed with methanol and stained for the 
presence of E3L or F3L (green) and dsRNA (Red). Nuclei (blue) were 
stained with DAPI. Merge panels represent an overlay of all three images.  
Yellow indicates the colocalization of E3L or F3L and dsRNA. 
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Fig. 14.  VACV and MPXV dsRNA levels in HeLa cells at 9 hpi.   
HeLa cells were infected at a MOI of 5 with VACV, VACV-E3L∆37N and 
MPXV. At 9 hpi the cells were fixed with methanol and stained for the 
presence of E3L or F3L (green) and dsRNA (Red). Nuclei (blue) were 
stained with DAPI. Merge panels represent an overlay of all three images.  
Yellow indicates the colocalization of E3L or F3L and dsRNA. 
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Fig. 16.  MPXV genomic replication in HeLa cells.  Cells were infected 
at a MOI 5 with VACVand MPXV.  Cells were harvested at 1, 2, 4, 6, 8, 10, and 
12 hpi and total DNA was extracted with phenol chloroform.  500 ng of total 
DNA was used for Real-time PCR with VACV-G8R specific primers.  Graph 
represents the fold change in genomic DNA as the fold change from input (1 
hpi).  Data presented are means with standard error of multiple experiments. 
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Fig. 17.  dsRNA western blot for VACV and MPXV dsRNA.  HeLa 
cells were either mock infected or infected with VACV and MPXV at a MOI 5.  
At 3, 6, 9, and 12 hpi and total RNA was extracted and an equal amount was 
transferred onto Hybond-N+ (Amersham) positively charged membrane.  
Western blot analysis was preformed with J2 anti-dsRNA antibodies.   
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Fig. 18.  ELISA for VACV and MPXV dsRNA levels.  HeLa cells were 
infected with VACV and MPXV at a MOI 5.  At 1, 2, 4, 6, 8, 10 and 12 hpi and 
total RNA was extracted and 500 ng of total RNA was added to ELISA plate.  
Signal was quantified by Luminescent plate reader.  Data presented are means 
with standard error of multiple experiments. 
 
  83 
  
Fig. 19.  In vitro PKR assay for VACV and MPXV dsRNA 
levels.  HeLa cells were either mock infected or infected with VACV 
and MPXV at a MOI 5.  At 1, 6, and 12 hpi and total RNA was extracted 
and 500 ng of total RNA was added to an in vitro kinase reaction and 
incubated at 30° for 10 min.  Samples were separated by SDS-PAGE and 
analyzed by western blot with antibodies specific for phosphorylated 
PKR.   
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Fig. 21.  MPXV genomic replication in JC Cells.  Cells were infected at 
a MOI 5 with VACV, VACV-E3L∆37N, and MPXV.  Cells were harvested at 
1, 2, 4, 6, 8, 10, and 12 hpi and total DNA phenol chloroform extracted.  500 ng 
of total DNA was used for Real-time PCR with G8R specific primers.  Graph 
represents the fold change in genomic DNA as the fold change from input (1 
hpi).  Data presented are means with standard error of multiple experiments. 
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Fig. 22.  VACV and MPXV dsRNA levels in JC cells.  JC cells 
were infected at a MOI of 5 with VACV, VACV-E3L∆37N and 
MPXV. At 6 and 9 hpi the cells were fixed with methanol and stained 
for the presence of E3L or F3L (green) and dsRNA (Red). Nuclei 
(blue) were stained with DAPI. Merge panels represent an overlay of 
all three images. Yellow indicates the colocalization of E3L or F3L and 
dsRNA. 
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Fig. 1. 23.  MPXV plaquing efficiency in the presence of IBT.  
BSC-40 cells were infected with ~ 50 PFUs of VACV, MPXV and 
VACV-A24R-R1 in the presence of increasing amounts of IBT.  At 3 
days post infection, the plaques were stained with crystal violet.  The 
plaques were counted and graphed as a percentage of the plaques 
present in the untreated cells.  
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Fig. 24.  MPXV replicates in the presence of IBT.  Multi-
cycle growth kinetics were performed in BSC-40 cells. The cells 
were infected with VACV, MPXV, and VACV-A24R-R1 at a MOI 
0.01 in the presence of absence of 60 µM IBT. Viruses were 
harvested at 0 and 72 hpi and titered by plaque assay in RK-E3L 
cells. Data presented are means with standard error of multiple 
experiments. 
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Fig. 25.  MPXV generates short mRNA transcripts.  Northern 
blot analysis with A10L DIG-labeled probe on RNA extracted from  
BSC-40 cells infected with VACV, MPXV, or VACV-A24R-R1 in 
the presence of absence of 30 µM IBT at a MOI of 5 at 9 hpi. Red 
lines indicate the average transcript size indicated on Table 1.1.  
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 Average Transcript 
Size (bp)  
VACV  7338  
VACV + IBT  0 
MPXV 3183  
MPXV + IBT  6710  
A24R-R1  3411  
A24R-R1 + IBT  9311  
Table 1.1.   VACV and MPXV A10L mRNA 
average sizesa from Fig 1.22.  
a Average size determined with Bio-Rad 
Quality One software.  
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CHAPTER 2 
 
TUMOR REGRESSION BY AN ATTENUATED ONCOLYTIC POXVIRUS 
ABSTRACT 
The development of oncolytic viruses as a therapy to treat cancer has been 
gaining interest in recent years.  Oncolytic viruses have either evolved naturally 
or have been designed to selectively replicate in and destroy cancerous cells 
leaving normal cells unharmed.  Vaccinia virus (VACV) has the potential to be an 
effective oncolytic virus due its natural tropism for tumor cells and the ease at 
which the virus can be manipulated to express tumor specific antigens or decrease 
any potential side effects associated with treatment.  It is well known that many 
cancerous tumors posses mutations in many of the cellular anti-viral signaling 
pathways, since many of these pathways can regulate cell growth.  Creating a 
mutation in the N-terminus of the VACV-E3L protein generates an oncolytic 
VACV that depends on dysregulated anti-viral signaling pathways for replication 
allowing for direct targeting of the cancerous cells.  Our results demonstrate that 
our potential oncolytic virus, VACV-E3L∆54N, is able to selectively replicate in 
numerous cancer cells lines and not in the normal non-cancerous cells.  
Additionally we show that VACV-E3L∆54N is safe and effective in causing 
tumor regression of MDA-MB-435s tumors in a SCID mouse xenograph model.  
Furthermore, we show that VACV-E3L∆54N is capable of spreading from treated 
tumors to untreated tumors in both a xenograph and syngeneic mouse model.     
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INTRODUCTION 
Oncolytic viruses are microorganisms that have been selected and/or 
engineered to replicate in and destroy cancerous cells, while sparing the normal 
non-cancerous cells.  It is well known that most tumors arise through genetic 
mutations causing cellular proteins to no longer function correctly.   Many of 
these mutations result in dysregulation of cellular anti-proliferative and anti-
apoptotic pathways allowing for uncontrolled cellular growth.  Therefore, 
Oncolytic viruses can be designed to specifically target cancer cells by exploiting 
these same cellular pathways that aid in tumor growth. 
The interferon (IFN) system is a potent anti-viral and anti-tumor system.  
IFNs have been shown to induce numerous proteins that play roles in anti-viral, 
anti-proliferative, angiostatic, and pro-apoptotic functions within the cell (31, 
110).  Consequently, many different forms of cancers have been reported to 
contain mutations in proteins required for signaling IFN, allowing the cells to be 
non-responsive to the normal anti-proliferative affects of IFN (6, 39, 48, 80, 90, 
122, 138).  In particular, numerous IFN-stimulated genes (ISGs) such as protein 
kinase R (PKR), 2’-5’ oligoadenylate synthetase (OAS), RNase L, and tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) have been reported to 
play roles in many of the anti-viral and anti-proliferative systems within the cell 
(7).  Therefore, deletions or mutations in any of these proteins and/or pathways 
can lead to an IFN resistant (IFNR) phenotype for cancerous cells.   
  Ras proteins not only affect cellular differentiation and proliferation, they 
can also alter the anti-viral IFN signaling cascade.  Mutations in Ras proteins that 
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lead to an overactivation of Ras have been associated with approximately 50% of 
colon cancers, 90% of pancreatic cancers, and 25% of other types of human 
cancers (16, 25, 82, 118).  In many types of cancer, PKR inhibition has been 
shown to be associated with an overactive Ras pathway by either Ras acting 
directly on PKR or by Ras inducing an inhibitor of PKR, the Ras-induced kinase 
inhibitor (RIKI) (33, 88).  In addition, deficiencies in PKR signaling have been 
shown to be vital for oncolytic virus replication in some types of cancerous cells 
(27, 45, 122, 124). 
  One current strategy being developed to fight cancer is to design viruses 
that selectively replicate and destroy cancerous cells leaving the normal non-
cancerous cell unharmed.  This approach takes advantage of the deficiencies in 
the cellular anti-viral defense pathways.   In particular, known IFN sensitive 
viruses have already been reported to be effective in treating some types of cancer 
based on their ability to selectively replicate within IFN non-responsive cancer 
cells (102, 134).  For example, herpes virus, influenza virus, newcastle disease 
virus (NDV), reovirus, poliovirus, measles virus and vesicular stomatitis virus 
(VSV) have all demonstrated the ability to propagate more efficiently in cancer 
cells than in normal IFN-responsive cells.  These viruses are either naturally 
selective for IFN-deficient cells (VSV, NDV, reovirus) or they were engineered to 
specifically target cancerous cells (Herpes virus, influenza virus, poliovirus, and 
measles virus).   
An oncolytic VACV offers several advantages over many of the other 
current oncolytic viruses being tested.  Due to the extensive use of VACV as the 
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vaccine to prevent against a smallpox infection, the safety profile and many of 
side effects associated with VACV have been established.  Additionally, VACV 
has the ability to infect a wide range of cell types thereby enhancing its ability to 
be effective at treating many different forms of cancer.  VACV also has the ability 
to stably incorporate up to 25 kb of foreign DNA allowing for a wide variety of 
genes to be incorporated into the viral genome and the generation of a tumor 
specific immune response (130).  Furthermore, VACV replication occurs entirely 
within the cytoplasm of an infected cell thereby preventing any viral DNA from 
being incorporated into the host genome.  Finally, several anti-virals (cidofivir 
and ST-246) are now available to treat any severe side effects that may arise 
following treatment with VACV.  (21).  
We have generated VACV recombinants that contain mutations in N and 
C-terminal domains of E3L (Fig. 28).  These viruses vary in their sensitivities to 
IFN and ability to inhibit PKR activation.   Both N-terminal and C-terminal 
domains of the VACV E3L protein have been shown to be necessary for complete 
inhibition of the PKR pathway, IFNR, and full pathogenesis in vivo (20, 75)(White 
and Jacobs, submitted).  Mutations in the VACV E3L gene generate viruses that 
are dependent on a dysregulated anti-viral IFN response pathway to successfully 
replicate.  Our hypothesis is that a VACV recombinant containing an N-terminal 
truncation in the E3L gene will generate a virus capable of selectively replicating 
in and killing cancerous cells, while leaving normal cells unharmed.   
In vitro studies have shown that VACVs expressing N-terminal 
truncations of E3L are not limited in their ability to replicate in a wide range of 
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cells (29, 113); however, the pathogenesis associated with these viruses is reduced 
in vivo (19).  The loss in pathogenicity was not due to a decrease in viral 
replication, but to a failure in the viruses’ ability to spread to the other tissues that 
normally support VACV replication (i.e. lungs and brain) (19).  In particular, a 
VACV that expresses an E3L deleted of the first 54 amino acids from the N-
terminus (VACV-E3L∆54N) (Fig. 28) was previously reported to be apathogenic 
in both C57BL/6 (immunocompetent) and SCID (immunocompromised) mice 
(19, 136).  Furthermore, VACV-E3L∆54N was shown to preferentially replicate 
in cancerous cells and not in the non-cancerous matched cell line (Fig. 29).  This 
suggests that VACV-E3L∆54N would make an excellent candidate for use as an 
oncolytic virus.    
Therefore, we explored whether VACV-E3L∆54N is a good oncolytic 
virus candidate.  We show that VACV-E3L∆54N induced tumor regression in 
both treated and untreated tumors in a SCID xenograph model.  Furthermore, we 
show a dose dependency for VACV-E3L∆54N to spread throughout the body and 
cause a regression in non-treated tumors.  Lastly, we demonstrate the successful 
replication of VACV-E3L∆54N in numerous glioblastoma cancer cell lines, 
suggesting the potential for VACV-E3L∆54N to cause tumor regression in a 
glioblastoma mouse model.  Therefore, we believe that VACV-E3L∆54N can be 
used as an alternative virotherapy or in combination with other known therapies to 
treat different types of cancer.    
 
 
  100 
MATERIALS AND METHODS 
 
Cells and Viruses.  MDA-MB-435S cells were maintained in Leibovitz’s 
L-15 medium with 2 mM L-glutamine, supplemented with 10% fetal bovine 
serum (FBS), 0.01 mg/mL insulin, 100 U/mL penicillin, and 0.1 mg/mL 
streptomycin. 4T1 cell were maintained in RPMI 1640 (ATCC) supplemented 
with 10 % FBS. U251, U373, U87, U118, and RK-E3L cells were maintained in 
Eagle’s Minimal Essential Medium (MEM) containing 5% FBS, while U343 and 
A172 were maintained in DMEM containing 5% FBS. All cells were incubated at 
37°C in the presence of 5% CO2.  Vaccinia virus strain Western Reserve(WR), 
designated as VACV, was used as the parental viruses to generate VACV-
E3L∆83N, VACV-E3L∆54N, VACV∆E3L as previously described (20). 
Multi-cycle Growth Kinetics.  All cancer cells were seeded in 6 well 
plates so they would be 80% confluent at the time of infection. The cells were 
infected with VACV, VACV∆E3L, and VACV-E3L∆54N at a multiplicity of 
infection (MOI) of 0.01. Infected cells were harvested at 3 and 72 hours post 
infection. Viral titers were determined by plaque assay in RK-E3L cells and 
stained with crystal violet at 48 hpi. 
In vitro protein labeling.  To assay for viral protein synthesis semi-
confluent monolayers of U251, U373, U87, and U343 cells were infected with 
VACV, VACV∆54N, and VACV∆E3L at a MOI of 5. Cells were labeled with 50 
μCi/ml of 35S-methionine/cysteine Protein Label Mix (Perkin-Elmer) at 2, 4, and 
6 hpi.  Thirty minutes prior to labeling, cells were washed twice with PBS and 
incubated with starvation media (DMEM without L-glutamine, L-methionine, and 
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L-cysteine (Cellgro)). Starvation media was removed and the labeling media 
(starvation media + 35S-methionine/cysteine 50 μCi/ml) was added and incubated 
at 37°C for 30 min. The cells were scraped, pelleted by centrifugation at 1,000 x g 
at 4°C for 10 min and then lysed using 75 ul of RIPA buffer (1XPBS, 1% NP40, 
0.5% sodium deoxycholate, 0.1% SDS, 200 mM NaF, 2 mM Na3VO4) for 10 min 
followed by centrifugation at 10,000 x g for 10 min. Supernatants were removed 
and an equal volume of 2X SDS-PAGE loading buffer (125 mM Tris-Cl, 20% 
glycerol, 4% SDS, 0.001% bromphenol blue, 0.2% 2-mercaptoethanol) was added 
to all samples. The proteins were separated by SDS-PAGE on 12% 
polyacrylamide gels, dried down on Whatmann filter paper and analyzed by 
autoradiography. 
Animal Studies.  All animal experiments were approved by the Arizona 
State University Institutional Animal Care and Use Committee.  Tumor 
xenografts were established as previously described (89).  For induction of MDA-
MB-435s tumors, 2x106 cells were trypsinized and resuspended in 100 µL of 
PBS.  For induction of 4T1 tumors, 1x105 cells were trypsinized and resuspended 
in 100 µL of PBS.  MDA-MB-435s cells were injected subcutaneously (s.c.) over 
each hind flank of four week old female SCID/bg mice (Charles River 
Laboratory).  4T1 cells were injected subcutaneously (s.c.) over each hind flank 
of 4 week old female BALB/c mice(Charles River Laboratory).  When the tumors 
reached 30-40 mm2, they were intratumorally injected with 1x105 or 1x107 pfu of 
virus in 10 µL of VACV-E3L∆54N, or PBS.  Tumors sizes and mice weights 
were monitored every other day.  
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Tumor Microscopy.  MDA-MB-435s tumors were induced s.c. in the 
hind flanks of female SCID/bg mice. Tumors were intratumorally injected with 
VACV-E3L∆54N at 1x107 pfu/ml. At 54 days post injection, the tumors were 
excised, fixed in 4% formalin, embedded in paraffin, and sectioned for 
histological analysis.  Sections were stained for VACV antigens with a rabbit 
polyclonal antiserum directed against total VACV proteins, followed by an HRP-
conjugated secondary antibody.  Sections were developed with a DAB substrate 
and counterstained with hematoxylin. 
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RESULTS   
VACV-E3L∆54N causes tumor regression in SCID Xenograph model.   
Previously, VACV-E3L∆54N was shown to successfully replicate in different 
cancer cells and not in the non-cancerous matched cell line (Fig. 29).  From this 
data, MDA-MB-435s cells were chosen for use in the SCID/bg xenograph model 
to analyze the potential of VACV-E3L∆54N as an oncolytic viral therapy.  In this 
model, bilateral tumors were induced over the hind flanks of each mouse by 
subcutaneous injection of MDA-MB-435s cells.  Following tumor formation, the 
right tumors were intratumorally injected with either PBS (mock-treatment) or 
VACV-E3L∆54N at a dose of either 1x105 (low) or 1x107 (high) pfu, while the 
left tumors remained untreated.  Tumor sizes were monitored every fourth day 
throughout the experiment.  Three mice were used for each treatment and tumor 
sizes are represented as the average of all three tumors for a given treatment.  For 
the mock-treated mice, the size of both the treated (Fig. 30A) and the untreated 
tumors (Fig. 30B) continued increase.  Treatment with the low dose of VACV-
E3L∆54N prevented the tumors from increasing in size, but their average size 
never decreased below the average size on the day treatment initiated (Fig. 30A).  
Conversely, the untreated tumors on the same mice continued to grow to a size 
equal to that of the mock-treated mice (Fig. 30B). Most notably, treatment with 
the high dose of VACV-E3L∆54N induced tumor regression in all three of the 
treated tumors as well as two of the three untreated tumors (Fig. 30A-B).  One of 
the untreated tumors from the set of mice treated with the high dose of VACV-
E3L∆54N began to increase at 20 days post treatment (data not shown).  
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However, the other two untreated tumors on the remaining mice in this treatment 
group were still regressing in size at the point the experiment was terminated 
(data not shown) and were similar in size to the treated tumors on the same 
mouse. 
Photographs taken from a prior experiment with the MDA-MB-435s cells 
were graciously provided Dr. Kelly Trainor and are representative of what was 
observed in the MDA-MB-435s SCID xenograph model.  MDA-MB-435s tumors 
were present on both hind flanks of the mock treated mice (Fig. 31A).  However, 
a decrease in tumor size occurred only for the treated tumor of the mice that 
received the low dose of VACV-E3L∆54N, while the untreated tumors were 
similar in size to the mock treated tumors (Fig. 31B).  Mice that received a high 
dose of VACV-E3L∆54N showed regression of the treated and the untreated 
tumors (Fig. 31C) 
To ensure VACV-E3L∆54N was not inducing pathogenesis in the SCID 
mice, mouse weight was recorded and compared over time.  Mock treated mice 
and the mice treated with both doses of VACV-E3L∆54N showed no significant 
weight loss at any point throughout the experiment (Fig. 32).  Overall, these data 
highlight the potential for VACV-E3L∆54N as a therapy to treat cancer since at 
its highest dose, VACV-E3L∆54N was proven safe and effective at inducing 
tumor regression using the SCID xenograph model.   
VACV-E3L∆54N spread to untreated tumors.   Since tumor regression 
was noted for the untreated tumors of mice treated with the high dose of VACV-
E3L∆54N, all remaining tumors were excised, sectioned, and stained with 
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antibodies specific for VACV.  The mock-treated tumors showed no evidence of 
VACV staining (Fig. 33A), while the untreated tumors excised from mice treated 
with the high dose of VACV-E3L∆54N show evidence of VACV staining (Fig. 
33A-B).  This confirms that VACV-E3L∆54N was able to spread from the treated 
tumors to the untreated tumors and was most likely responsible for causing the 
regression in tumor sizes of the untreated tumors that were observed.    
VACV-E3L∆54N replicates in glioblastoma cells lines.  With the 
success of VACV-E3L∆54N inducing tumor regression in the MDA-MB-435s 
SCID model, we then wanted to see if VACV-E3L∆54N could be successful at 
treating other types of cancer.  We first chose to examine the ability of VACV-
E3L∆54N to replicate in various glioblastoma cell lines, since they are also 
known to have deficiencies in their IFN anti-viral signaling pathways (49).  Multi-
step growth kinetics was performed on U251, U87, U343, U373, A172, and U118 
with VACV, VACV-E3L∆54N, and VACV∆E3L.  VACV replicated to high 
titers in all cell lines, while VACV∆E3L replication was inhibited in all six cell 
lines (Fig. 34).  VACV-E3L∆54N replicated to high titers in four of the cell lines 
tested (U87, U251, U118, and U373), to an intermediate level in the A172 cells, 
and VACV-E3L∆54N replication was inhibited in the U343 cell line. 
We confirmed replication of VACV-E3L∆54N in these same cell lines by 
by 35S methionine protein labeling.  Glioblastoma cells were infected with VACV 
and VACV-E3L∆54N and protein lysates were isolated at 2, 4, and 6 hpi.  
Following infection, if the viruses are replicating in the cells there should be a 
transition from cellular protein synthesis to viral protein synthesis.  In the U251 
  106 
and U343 cell lines, VACV was able to induce the transition from cellular protein 
synthesis to viral protein synthesis (Fig. 35, red arrows).  Additionally, viral 
protein synthesis was also observed in the A172 and U373 cell lines (data not 
shown).  For VACV-E3L∆54N, viral protein synthesis was observed in the U251 
cell line, but not the U343 cell line (Fig. 35).  Similar to VACV, viral protein 
synthesis for VACV-E3L∆54N was also observed in the A172 and U343 cell 
lines (data not shown).  These data correlate with the replication data, in these 
cells where VACV-E3L∆54N grew to high titers, the transition from cellular 
protein synthesis to viral protein synthesis was observed.  Based on these data we 
believe that VACV-E3L∆54N may be successful in treating glioblastoma tumors 
in vitro. 
VACV-E3L∆54N did not cause tumor regression in Glioblastoma 
SCID mouse model.   Based on the results obtained from the replication data 
above, we chose to look at the ability of VACV-E3L∆54N to cause tumor 
regression of U251, U373, and U118 tumors within SCID/bg mice.   Similar to 
the previous in vivo study with the MDA-MB-435s cells, bilateral tumors were 
induced over the hind flanks of each mouse by subcutaneous injection of the 
U251, U373, and U118 cells.  The right tumors were intratumorally injected with 
either PBS (mock-treatment) or VACV-E3L∆54N at a dose of 1x107 pfu, while 
the left tumors remained untreated.  Tumor sizes were monitored every other day 
for the length of the experiment.  Three mice were used for each treatment and 
tumor sizes are represented as the average of all three tumors for a given 
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treatment.  Regrettably, VACV-E3L∆54N was not able to cause regression of any 
of the tumors for all three cell lines (data not shown).   
VACV-E3L∆54N treatment of 4T1 tumors in BALB/c mice.  Since 
VACV-E3L∆54N was successful at causing tumor regression of the MDA-MB-
435s cells in the immunocompromised SCID/bg mouse model, we wanted to 
determine if VACV-E3L∆54N would have a similar effect in an 
immunocompetent model.  4T1 mammary tumor cells were injected 
subcutaneously under each hind flank of BALB/c mice.  Once the tumors were 
palpable, they were either treated three times with PBS or 1x107 pfu of VACV-
E3L∆54N over the course of six days.  Three mice were used for each treatment 
and tumor sizes are represented as the average size of all three tumors for a given 
treatment.  VACV-E3L∆54N treatment moderately reduced the growth of the 
both the untreated and treated tumors (Fig. 36).  Beginning at day 11, the 
difference in the mean tumor size between mock treated tumors and VACV-
E3L∆54N treated tumors was significant each day until the endpoint of the 
experiment (Fig. 36, P < 0.05).  The average tumor sizes for the untreated tumors 
were similar in size to the VACV-E3L∆54N treated tumors and were smaller than 
the tumors on the mock treated mice; however the data are not statistically 
significant.  Large scabs were observed on both the treated and the untreated 
tumors of all the VACV-E3L∆54N treated mice (Fig. 37, B), while the mock-
treated tumors appear normal (Fig. 37, A).  These data suggest that VACV-
E3L∆54N has the potential to be an effective oncolytic virus, but the virus may 
need to be improved to have a more dramatic and lasting effect.   
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DISCUSSION 
Tremendous advances have been made in developing new cancer therapies 
over recent years; however, the number of cancer related deaths continue to rise.  
Oncolytic viruses offer several advantages over conventional anti-cancer therapies 
thanks to recent advancements in molecular biological techniques that make it 
easy to genetically engineer viruses to selectively target cancerous cells or reduce 
any side effects that may be associated with the viral treament.  Additionally, 
viruses can be engineered to express tumor specific antigens that may allow the 
host’s immune system to mount a response against the tumor or even prevent the 
initial formation of a tumor.  
One strategy currently being developed to selectively target oncolytic 
viruses to cancerous cells is to take advantage of the same cellular pathways that 
promote tumor growth (91).   In the past, IFN has been utilized as an anti-cancer 
therapy, but IFN treatment had limited success (105). This is not surprising since 
many types of cancer are known to have deficiencies in their ability to respond to 
IFN.  IFNs can play a critical role in activation of the adaptive immune response 
allowing the host to mount an immune response against the tumors and cause 
their destruction (43).  Furthermore, tumors also have evolved to become non-
responsive to IFN, given that many ISGs are responsible to inducing apoptosis 
and halting cell growth (122).  Specifically, mutations that alter the function 
RNase L and PKR have been suggested to enhance both the establishment and the 
progression of some types of cancer (40, 115).  Additionally, PKR can directly 
interact with and affect tumor suppressor p53 transcription and phosphorylation 
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(40).  Abnormally high levels of PKR have been detected in mammary 
carcinomas, but the protein appears to be unable to phosphorylate eIF-2α (106). 
Recently viruses known to be IFN sensitive, such as VSV, NDV, and 
reovirus, were able to preferentially replicate in IFN non-responsive cancer cells, 
while replication was inhibited in the normal IFN responsive cells (102, 123).  
This ability allows these viruses to selectively replicate in and destroy the 
cancerous cells, while leaving the normal cells unharmed.  Clinical trials with 
many of these oncolytic viruses tested show that they are safe, but their 
therapeutic potency is limited and there is no systemic spread of the virus to distal 
tumors (68).  As previously mentioned, an oncolytic VACV offers several 
advantages over many of the other current oncolytic viruses and these advantages 
may permit VACV to be a more effective as an oncolytic viral therapy.       
VACV has been shown to express numerous proteins that play vital roles 
in preventing activation of the IFN anti-viral immune response.  In particular, the 
E3L protein is important for conferring the IFNR phenotype of VACV (113).  
Deletion of E3L gene severely attenuates the virus by restricting virus host range 
and rendering it sensitive to the effects of IFN (11, 13, 29).  Studies with VACVs 
expressing E3L proteins containing truncations in the N-terminus are unaffected 
in terms of host range (29, 113), but are reduced in pathogenesis in vivo (19).  
Additionally, these viruses vary in their sensitivities to IFN and the ability to 
inhibit PKR activation causing them to be dependent on a non-functional IFN 
response for replication.   For example, VACV-E3L∆54N is known to 
apathogenic in both C57BL/6 (immunocompetent) and SCID 
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(immunocompromised) mice (19, 136).  However, the virus will preferentially 
replicate in cancerous cells and not in the normal, non-cancerous matched cell 
line.  This suggests that VACV-E3L∆54N would make an excellent candidate for 
use in cancer therapy as an oncolytic virus.    
VACV-E3L∆54N replicated to high titers in the Hs578T breast cancer cell 
line, but not in the normal Hs578Bst that were isolated from the same patient.  
Since VACV-E3L∆54N was unable to replicate in the normal Hs578T cells but 
was able to replicate in the Hs578Bst cells, this suggests the virus has the ability 
selectively replicate in cancerous cells.  This is an important feature for any 
potential oncolytic virus as this would limit any potential side effects that may 
arise during the treatment.  VACV-E3L∆54N also replicated in three other cell 
lines (MCF-7, MDA-MB-435s, and T47D), but replication was inhibited in the 
SKBR-3 and MDA-MB-468 cancer cell lines.  It was determined that the inability 
to replicate in the two other cancer cell lines was due to a lack of protein synthesis 
(unpublished data).  Experiments to determine why VACV-E3L∆54N was not 
able to replicate in SKBR-3 and MDA-MB-468 cells could offer important insight 
as to how to improve the oncolytic potential of VACV-E3L∆54N thereby making 
it more effective as a cancer therapeutic.   
To determine the oncolytic potential of VACV-E3L∆54N in vivo, we 
implanted MDA-MB-435s tumors in SCID/bg mice.  In this bilateral tumor 
model, right side tumors were treated with either a low dose (1x105 pfu) or high 
dose (1x107 pfu) of VACV-E3L∆54N.  The left side tumors remained untreated to 
determine if VACV-E3L∆54N was capable of treating distant metastasized 
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tumors.  At the highest dose of VACV-E3L∆54N, we observed a regression in 
both tumors, but the low dose only caused regression of the treated tumors.  
Immunohistochemisty staining of the untreated tumors from the mice treated with 
the high dose of VACV-E3L∆54N also confirmed the presence of the virus in the 
untreated tumors. These data suggest that VACV-E3L∆54N has the potential to 
be an effective oncolytic therapy and at a high enough dose, VACV-E3L∆54N is 
able to spread and cause regression of distant tumors.  The ability of the virus to 
spread to distant tumors is an important characteristic for an effective oncolytic 
virus, as this would enable the virus to seek out any tumor cells or metastases, in 
hopes of lowering the probability of tumor reoccurrence.   
Using live replication competent viruses to treat patients comes with the 
inherent risk of the patients developing severe side effects associated to the virus.  
The SCID/bg mice served as an excellent model to analyze VACV-E3L∆54N 
oncolytic potential in vivo, but it also allowed us to gain a better understanding of 
VACV-E3L∆54N safety profile.  N-terminal mutations in the VACV-E3L protein 
are known to cause attenuation (20).  In the case of VACV-E3L∆54N, the 
attenuation is believed to be due to the instability of the truncated E3L protein 
(unpublished data).  Monitoring mice weights throughout the experiment enabled 
us to show that VACV-E3L∆54N may be a safe option for immunocompromised 
individuals, since weights remained the same or even increased throughout the 
experiment.  This is a good indication that the mice were healthy and no 
detectable side effects were associated with treatment by VACV-E3L∆54N.    
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To determine if VACV-E3L∆54N could also be effective at treating other 
types of cancer, we chose to look at the ability of VACV-E3L∆54N to replicate in 
six different glioblastoma cell lines.  VACV-E3L∆54N was able to replicate in 
five out of the six cell lines tested.  Therefore, determining why VACV-E3L∆54N 
was not able to replicate in the U343cell line could be beneficial for improving 
VACV-E3L∆54N and making it more effective against a wider range of tumors.   
To ascertain the possibility of VACV-E3L∆54N inducing tumor 
regression of glioblastoma tumors in vivo, we induced bilateral tumors in 
SCID/bg mice with U251, U373, and U118 cells and the tumors were treated with 
1x107 pfu of VACV-E3L∆54N.  Unfortunately, VACV-E3L∆54N was not able to 
cause regression of the tumors in this model.  However, we do not believe it was 
an inability of the virus to replicate in the cells, since in vitro, VACV-E3L∆54N 
replicated to high titers in all three cell lines.  It is also highly unlikely the mice 
mounted an immune response against the virus, since the mice were severely 
immune comprised.  We believe the inability of VACV-E3L∆54N to cause a 
regression in the glioma tumors may have been due to the highly vascular nature 
of these tumors. Upon treatment with VACV-E3L∆54N, a significant amount of 
blood was excreted from the injection site.  Based on this, we do not believe a 
sufficient amount VACV-E3L∆54N was injected into the tumor to have an effect 
and lead to a regression in size.  Given that glioblatomas are brain tumors, a 
logical next step would be to look at the ability of VACV-E3L∆54N to reduce 
glioma tumors in an intracranial model.  This model has proven effective in the 
past to analyze the ability of myxoma virus to reduce glioma tumor sizes in vivo 
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(8).  In an intracranial model myxoma virus with U251 and U87 tumors, treatment 
with myxoma virus resulted in smaller tumors and prolonged the life expectancy 
of the mice (8). 
Glioblastoma tumors cells are believed to have a non-functional IFN 
response, since a common characteristic for many of these types of cells is to have 
an overactivation of the epidermal growth factor receptor (EGFR) and the 
platelet-derived growth factor receptor (PDGFR)(49).  Over-activation of these 
receptors can lead to a hyperactivation of the Ras pathway and either directly or 
indirectly lead to an inhibition of the PKR pathway (88).  This overactivation of 
the Ras pathway could allow VACV-E3L∆54N to selectively replicate in the 
cancerous brain cells and not in the normal cells.  Previously, VACV-E3L∆83N, 
deleted of the first 83 amino acids from the N-terminus of E3L, was not able to 
spread from the initial site of infection in mice following an intracranial injection 
(19).  This would suggest that VACVs containing N-terminal deletions of E3L are 
unable to successfully replicate and spread to normal cells within the brain, 
making them good candidates for continued study into their efficacy as a 
therapeutic for glioblastoma tumors.   
An important step in determining the efficacy of an oncolytic virus is to 
test the ability of the virus to treat tumors in a syngeneic immunocompetent 
model.  A limiting factor that could decrease the effectiveness of oncolytic virus 
is the host’s immune system.  In an immunocompromised model, a virus can 
replicate in the tumor cells and spread throughout the body uncontrollably.  
Conversely, an immunocompetent immune system in a mouse could limit the 
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effectiveness of an oncolytic virus by inhibiting replication and spread to distant 
tumors.   We utilized the BALB/c 4T1 mammary tumor model to investigate the 
ability of VACV-E3L∆54N to cause tumor regression in an immunocompetent 
model.  The VACV-E3L∆54N treated tumors continued to increase, but at 
reduced rate as compared to the mock treated mice.  We believe measuring the 
volume of the tumor rather than the total tumor area would have provided a better 
measurement of tumor size since many of VACV-E3L∆54N tumors had a 
concave shape, whereas the mock treated tumors were bulbous in shape.  Even 
though the VACV-E3L∆54N treatment did not induce a complete regression of 
the 4T1 tumors, if was able to reduce the rate of tumor growth, plus the virus 
seemed to translocate to the untreated tumor.  However, it is possible that VACV-
E3L∆54N did not enter the untreated tumors, but the virus infection in the treated 
tumor triggered a global anti-tumoral immune response against the untreated 
tumors.   Immunohistochemisty on sections of the untreated tumors from the 
VACV-E3L∆54N treated mice will help determine if the virus was present in the 
untreated tumors.  Additionally, further experiments may help determine if 
VACV-E3L∆54N was responsible for the observed decrease in tumor growth or if 
the virus triggered an immune response against the tumor(s).  If VACV-E3L∆54N 
was able to cause the mice to break tolerance of the tumors, that would be 
significant in the development of oncolytic viruses.  The host’s immune system 
could target any remaining tumor cells and lower the chance of reoccurrence or 
spread without any further help from chemotherapeutics or other oncolytic 
viruses.  Furthermore, experiments looking at tumor regression with 4T1 cells in 
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the mammary fat pads of mice could also offer valuable information considering 
4T1 tumors do not normally occur on the hind flanks of mice.   
VACV-E3L∆54N did not induce a complete regression of the 4T1 tumors, 
suggesting that the virus needs to be improved to make it a more effective 
oncolytic virus.  One strategy that has proven effective in the past to enhance the 
spread of VACV is to increase the production of the extracellular enveloped virus 
(EEV) form of VACV (69).  During replication, VACV forms two different types 
of enveloped viruses, either the cell-associated enveloped virus (CEV) or EEV.  
The CEV forms of VACV remain attached to the membranes of infected cells and 
spread is limited to neighboring cells, while the EEV forms are released form 
infected cells and spread systemically through the host (23, 117).  The IHD-J 
strain of VACV is known to produce more EEV forms of VACV than the WR 
strain of VACV due to a point mutation in the A34R gene (15, 83).  By generating 
a VACV-E3L∆54N that expresses the A34R gene of the IHD-J strain of VACV, 
the virus may be able to spread thoroughtout the host more efficiently.   
 Increasing the percentage of EEV formed during a VACV infection may 
also offer another advantage to a potential oncolytic virus.  The EEV forms of 
VACV have an additional lipid bilayer obtained from the cellular membrane and 
only one antigenic viral protein is exposed on the surface of the virus.  As a result, 
these forms of the virus are more resistant to complement and neutralizing 
antibodies (55, 116).  Theoretically, this should increase VACV-E3L∆54N’s 
chances of infecting a greater number of the tumor cells and spreading to distant 
tumors before the host’s immune system starts to target the virus.  Even though 
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increasing the amount of EEV produced enhances the spread of the virus, it does 
not increase virus pathogenicity (69).  This would suggest that a VACV-
E3L∆54N that prduces more EEVs would still have the same safety profile, but 
experiuments need to be perfomed to the apathogenic pheotype of the 
recombinant VACV-E3L∆54N in SCID mice is still retained.   
With the number of people being diagnosed with cancer increasing every 
year, new and improved treatments and/or cancer therpies must be developed.  
The conventional therapies for many types of cancer (i.e. surgery, radiation, 
and/or chemotherapy) are effective to a point.  Due to the highly infiltrative nature 
and the ability to develop resistance, tumors continue to reoccur and as a result, 
more efficient therapies need to be developed.  Oncolytic viruses have the 
potential to become a valuable alternative to the current therapies or they can be 
used in conjunction with conventional therapies to develop more efficient 
treatment regimes to fight cancer.   
 
   
 
 
  
  
 
 
 
  
Fig. 28.  Oncolytic VACV recombinants.  The VACV-E3L protein 
contains an N-terminal Z-nucleic acid binding domain, while the C-terminus 
contains the dsRNA binding domain.  E3L N-terminal recombinants were 
generated to contain a partial deletion of the N-terminus (∆54N) or a complete 
deletion of the Z-NA binding domain (∆83N), also then entire E3L protein was 
replaced with LacZ in ∆E3L.  The relative ability of each virus to inhibit PKR 
activation is shown on the left. 
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Fig. 29.  VACV-E3L∆54N replication in various cancer cell lines.  
Multi-cycle growth kinetics were performed in various cancer cell lines. 
The cells were infected with VACV, VACV∆E3L, and VACV-E3L∆54N 
at a multiplicity of infection (MOI) of 0.01. At 72 hpi the cells were 
harvested and viruses were tittered in Rk-13 cells.  This figure was kindly 
provided by Dr. Kelly Trainor. 
  118 
Fig. 30.  MDA-MB-435s tumor regression by VACV-E3L∆54N.  
MDA-MB-435s tumors were induced by subcutaneously injection over the 
hind flanks of SCID/bg mice.  Right side tumors (A) were either treated 
with PBS or 1x105 and 1x107 pfu of VACV-E3L∆54N.  Left side (B) 
remained untreated.  Tumor sizes were monitored for 54 days post 
treatment.  Tumor sizes represent the average tumor size per treatment 
with 3 mice per treatment.      
  119 
  
 
Fi
g.
 3
1.
  M
D
A
-M
B
-4
35
s t
um
or
s  
tre
at
ed
 w
ith
 V
A
C
V
-E
3L
∆
54
N
.  
 Im
ag
es
 a
re
 
re
pr
es
en
ta
tiv
e 
of
 th
e 
m
ic
e 
se
en
 a
t t
he
 e
nd
 o
f t
he
 e
xp
er
im
en
t t
ha
t w
er
e 
ei
th
er
 m
oc
k-
tre
at
ed
 
(A
) o
r t
re
at
ed
 w
ith
 1
 x
 1
05
 (B
) o
r 1
 x
 1
07
 (C
) p
fu
 o
f V
A
C
V
-E
3L
∆
54
N
.  
Im
ag
es
 w
er
e 
ki
nd
ly
 p
ro
vi
de
d 
by
 D
r. 
K
el
ly
 T
ra
in
or
.  
 
 
  120 
 Fig. 32.  SCID/bg mice weights post VACV-E3L∆54N treatment.  
MDA-MB-435s tumors were induced by subcutaneously injection over the 
hind flanks of SCID/bg mice.  Right side tumors were either treated with 
PBS or 1x105 and 1x107 pfu of VACV-E3L∆54N.  Mice weights were 
monitored and are represented as the average percent of initial weight for 
all three mice per treatment. 
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 Fig. 33.  VACV-E3L∆54N spread to untreated tumors.  MDA-MB-
435s tumors were induced over the hind flanks of SCID/bg mice.  Right 
side tumors were treated with either PBS or 1 x 107 pfu of VACV-
E3L∆54N and at 54 days post treatment the remaining tumors were 
removed and sectioned for histological examination.  Sections were stained 
for VACV antigens and developed with DAB substrate.  Sections were 
counterstained with hematoxylin.  A, untreated tumor from the mock-
treated mice. B and C, untreated tumors from the mice that received 1 x 107 
pfu/mL of VACV-E3L∆54N.  Positive VACV staining is evident by the 
brown coloration present in B and C.  
  122 
 
  
  123 
  
Fig. 34.  VACV-E3L∆54N replication in Glioblatoma cell lines.  
Multi-cycle growth kinetics were performed in various cancer cell lines. 
The cells were infected with VACV, VACV∆E3L, and VACV-E3L∆54N 
at a MOI of 0.01. At 72 hpi the cells were harvested and viruses were 
tittered in Rk-13 cells.  Data presented are means with standard error of 
multiple experiments. 
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Fig. 35.  Expession of VACV-E3L∆54N proteins in glioblatoma 
cell lines.  U251 and U343 cells were either mock-infected or infected 
with VACV (A) and VACV-E3L∆54N (B) at a MOI of 5. At the times 
indicated, proteins were labeled with 35S methionine and protein lysates 
were isolated.  Samples were analyzed by SDS-PAGE and 
autoradiography.  Red arrows indicate viral proteins.     
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 Fig. 36.  VACV-E3L∆54N therapy of 4T1 tumor.  BALB/c were 
injected subcutaneously over the hind flanks with 1x105 4T1 cells. Palpable 
tumors appeared in 10 days and the right side (T) tumors were treated with 
either PBS or 1 x 107 pfu of VACV-E3L∆54N.  Left side tumors remained 
untreated.  Tumor sizes were determined as described previously in the 
materials and methods.  * Significant differences between mock and VACV-
E3L∆54N treated tumors.  Error bars represent standard error. 
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Fig. 37.  4T1 tumors treated with VACV-E3L∆54N.  4T1 tumors 
were induced over each hind flank of BALB/c mice. Right side tumors 
were treated three times with PBS (A) or 1x107 pfu of VACV-E3L∆54N 
(B).  Images were taken 13 days post treatment.   
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OVERALL DISCUSSION 
Vaccinia virus (VACV) is known to express numerous proteins that play 
pivotal roles in preventing the activation of the host’s anti-viral immune response.  
One protein in particular, E3L, has been shown to inhibit the cellular interferon 
(IFN) anti-viral immune response and deletion of E3L leads to virus attenuation 
and severely limits the host range of the virus (11-13).  The VACV E3L gene 
encodes for two proteins, p25 and p20 that binds to the double-stranded RNA 
(dsRNA) produced during a viral infection and sequesters it from many of the 
intracellular dsRNA pathogen associated molecular pattern (PAMP) receptors 
involved in activating the anti-viral immune response (30, 137, 144).  Deletion of 
the E3L gene is severely detrimental to VACV, leading to a loss of the IFN 
resistance (IFNR) phenotype (11, 29), a restriction in viral host range (11, 13, 29), 
and a reduction in viral pathogenesis (20) .  Full-length E3L, p25, consists of two 
separate domains, an N-terminal Z-nucleic acid binding domain (Z-NA-BD) and a 
C-terminal dsRNA binding domain (dsRNA-BD) (51-52).  The naturally 
occurring truncated form of E3L, p20, is deleted of the first 37 amino acids from 
the N-terminus.  Overall, the VACV E3L protein plays a pivotal role in immune 
evasion of the host’s defenses.  
The C-terminal dsRNA-BD of E3L is highly conserved among poxviruses 
(120).  It has been fairly well characterized in its function of binding to dsRNA 
and sequestering it from the cellular PAMP receptors (28-29).  Conversely, the 
function of the N-terminal Z-NA-BD is fairly less understood.  The N-terminal Z-
NA-BD of E3L is also well conserved among many poxviruses, but to a lesser 
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extent as compared to the C-terminal dsRNA-BD.  In the past, the N-terminal 
domain was not required for replication and IFNR in vitro, but it was required for 
full pathogenesis in mice (19).  However, recently the N-terminal domain was 
shown to be necessary for replication in the JC mammary adenocarcinoma cell 
line and IFN resistance in mouse embryo fibroblasts (Trainor and Jacobs, in 
preparation) (White and Jacobs, submitted).  Therefore, these two cell lines may 
play an important role in determining the function of the N-terminus of E3L. 
  It is known that truncations or a complete deletion of the E3L N-terminus 
can severely decrease pathogenesis of the virus in vivo (19), so it was surprising 
to learn that for MPXV, a virus believed to make only the truncated p20 version 
of E3L, is still able to cause a severe disease in humans.  One of the main goals of 
the research presented in this dissertation was to gain a better understanding of 
how MPXV is able to prevent activation of the innate immune response.  Since 
the MPXV protein is deleted of the first 37 amino acids, theoretically the virus 
should have inhibited the anti-viral immune response more similar to VACV-
E3L∆37N than VACV.  However, we show that MPXV possessed an ability to 
inhibit the anti-viral immune response more similar to VACV and MPXV is also 
able to grow in the JC cells, where previously the full E3L N-terminal domain 
was shown necessary for replication (Trainor and Jacobs, in preparation). These 
data suggest that MPXV has evolved another mechanism to prevent the activation 
of the anti-viral response as a way to compensate for the loss of the first 37 amino 
acids from the N-terminus of F3L.  We then looked at dsRNA levels in MPXV 
infected cells, since the VACV E3L protein is known to play a pivotal role in 
  130 
preventing activation of the anti-viral pathways activated by dsRNA.  Ultimately, 
we show that MPXV produces less dsRNA than VACV through the course of 
infection.  The virus accomplishes this by generating shorter intermediate and late 
viral transcripts than VACV at late times post infection, a time when majority of 
dsRNA is formed (35).  Therefore, is the N-terminal Z-NA-BD of E3L also 
playing a role dsRNA sequestration, along with the C-terminal dsRNA-BD?  We 
hypothesize that the N-terminal domain of E3L may be required to fully sequester 
the longer dsRNAs generated during a VACV infection and that is why the ability 
to inhibit PKR and cause pathogenesis is reduced for VACV-E3L∆37N.   
The other main goal of the research presented in this dissertation was to 
determine if a recombinant VACV could be utilized as an oncolytic virus to treat 
cancer.  It is well known that many types of cancers are deficient in their ability to 
respond and prevent against a viral infection, since many of the pathways that 
promote cellular division are also involved in the cellular anti-viral immune 
response (6, 39, 48, 80, 90, 122, 138).  Oncolytic viruses specifically replicate in 
cancerous cells while leaving the normal cells unharmed.  An oncolytic poxvirus 
would have great advantages over many current oncolytic viruses.  Their ability to 
infect a wide range of cells would allow them to be effective against many 
different types of cancer.  In addition, poxviruses can be easily manipulated to 
either make them less pathogenic to decrease any side effects or make them 
express foreign antigens that could help in producing a cellular immune response 
against the tumor.   Most importantly, VACV was widely used as the vaccine to 
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prevent against smallpox infections, so the safety profile and side effects 
associated with VACV treatment have been well defined.   
Our hypothesis was that VACV-E3L∆54N would make a great candidate 
for an oncolytic virus due to its ability to selectively replicate in cancerous cells 
and not in normal non-cancerous cells (Trainor and Jacobs, in preparation) and 
due to its apathogenic phenotype in SCID mice (136).  We analyzed the ability of 
VACV-E3L∆54N to cause regression of MDA-MB-435s tumors in a SCID 
xenograph model.  VACV-E3L∆54N was successful in causing regression of 
MDA-MB-435s tumors, especially at the highest dose of virus (1x107 pfu) where 
a regression of both the treated and the untreated tumors was observed.  It was 
determined that the regression of the untreated tumors was due to VACV-
E3L∆54N translocating from the treated tumor to the untreated tumor.  This is an 
important characteristic when designing an oncolytic virus, since this would allow 
the virus to travel throughout the body destroying all the cancerous cells and 
decreasing the probability of tumor reoccurrence.   
We then explored VACV-E3L∆54N’s ability to cause tumor regression of 
glioblastoma tumors.  These types of tumors are also known to be deficient in the 
ability to respond to a viral infection.  Unfortunately, VACV-E3L∆54N did not 
cause regression of the glioblastoma tumors.  However, due to the vascular nature 
of these tumors VACV-E3L∆54N may have been unable to infect the tumor cells.  
Tumors were not analyzed for the presence of VACV antigens, so it is impossible 
to determine if any virus even infected any of the tumor cells.  The use of an 
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intracranial model may be more efficient in determining if VACV-E3L∆54N can 
lead to glioma tumor regression.  
An analysis of an oncolytic virus’ ability to cause tumor regression in an 
immunocompetent model is important in determining how effective the virus 
would be as a cancer therapy.  The host’s immune system could limit the 
effectiveness of the virus by destroying it before it causes regression of the tumor.  
In the 4T1 syngeneic BALB/c mouse model, VACV-E3L∆54N appeared to be 
moderately effective and decreased the rate at which the tumors were growing, 
but it was not effective enough to cause complete regression of the 4T1 tumors.  
More than likely the host’s immune system played some role in limiting VACV-
E3L∆54N effectiveness, so engineering VACV-E3L∆54N to hide from the 
immune system and spread more efficiently, without increasing pathogenesis, 
may improve the virus’ effectiveness at causing tumor regression in an 
immunocompetent model.   
The research described in this dissertation to gain a better understanding 
of the function associated with the N-terminus of the VACV E3L protein.  With a 
better understand of the VACV E3L N-terminal Z-NA-BD, it will be possible to 
design effective VACV based vaccines and therapies. 
  
  133 
REFERENCES 
1. Alcami, A., A. Khanna, N. L. Paul, and G. L. Smith. 1999. Vaccinia 
virus strains Lister, USSR and Evans express soluble and cell-surface 
tumour necrosis factor receptors. J Gen Virol 80 ( Pt 4):949-59. 
2. Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 
beta encoded by vaccinia virus: a novel mechanism of virus modulation of 
the host response to infection. Cell 71:153-67. 
3. Alcami, A., and G. L. Smith. 2002. The vaccinia virus soluble interferon-
gamma receptor is a homodimer. J Gen Virol 83:545-9. 
4. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. 
Recognition of double-stranded RNA and activation of NF-kappaB by 
Toll-like receptor 3. Nature 413:732-8. 
5. Appleyard, G., and H. J. Way. 1966. Thiosemicarbazone-resistant 
rabbitpox virus. Br J Exp Pathol 47:144-51. 
6. Bachmann, A., B. Hanke, R. Zawatzky, U. Soto, J. van Riggelen, H. 
zur Hausen, and F. Rosl. 2002. Disturbance of tumor necrosis factor 
alpha-mediated beta interferon signaling in cervical carcinoma cells. J 
Virol 76:280-91. 
7. Barber, G. N. 2001. Host defense, viruses and apoptosis. Cell Death 
Differ 8:113-26. 
8. Barrett, J. W., L. R. Alston, F. Wang, M. M. Stanford, P. A. Gilbert, 
X. Gao, J. Jimenez, D. Villeneuve, P. Forsyth, and G. McFadden. 
2007. Identification of host range mutants of myxoma virus with altered 
oncolytic potential in human glioma cells. J Neurovirol 13:549-60. 
9. Bass, B. L., K. Nishikura, W. Keller, P. H. Seeburg, R. B. Emeson, M. 
A. O'Connell, C. E. Samuel, and A. Herbert. 1997. A standardized 
nomenclature for adenosine deaminases that act on RNA. RNA 3:947-9. 
  134 
10. Bayliss, C. D., and R. C. Condit. 1993. Temperature-sensitive mutants in 
the vaccinia virus A18R gene increase double-stranded RNA synthesis as 
a result of aberrant viral transcription. Virology 194:254-62. 
11. Beattie, E., K. L. Denzler, J. Tartaglia, M. E. Perkus, E. Paoletti, and 
B. L. Jacobs. 1995. Reversal of the interferon-sensitive phenotype of a 
vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol 
69:499-505. 
12. Beattie, E., E. B. Kauffman, H. Martinez, M. E. Perkus, B. L. Jacobs, 
E. Paoletti, and J. Tartaglia. 1996. Host-range restriction of vaccinia 
virus E3L-specific deletion mutants. Virus Genes 12:89-94. 
13. Beattie, E., E. Paoletti, and J. Tartaglia. 1995. Distinct patterns of IFN 
sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant 
viruses. Virology 210:254-63. 
14. Beattie, E., J. Tartaglia, and E. Paoletti. 1991. Vaccinia virus-encoded 
eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology 
183:419-22. 
15. Blasco, R., J. R. Sisler, and B. Moss. 1993. Dissociation of progeny 
vaccinia virus from the cell membrane is regulated by a viral envelope 
glycoprotein: effect of a point mutation in the lectin homology domain of 
the A34R gene. J Virol 67:3319-25. 
16. Bos, J. L. 1989. ras oncogenes in human cancer: a review. Cancer Res 
49:4682-9. 
17. Bowie, A. G. 2007. Translational mini-review series on Toll-like 
receptors: recent advances in understanding the role of Toll-like receptors 
in anti-viral immunity. Clin Exp Immunol 147:217-26. 
18. Bowie, A. G., and L. Unterholzner. 2008. Viral evasion and subversion 
of pattern-recognition receptor signalling. Nat Rev Immunol 8:911-22. 
19. Brandt, T., M. C. Heck, S. Vijaysri, G. M. Jentarra, J. M. Cameron, 
and B. L. Jacobs. 2005. The N-terminal domain of the vaccinia virus 
  135 
E3L-protein is required for neurovirulence, but not induction of a 
protective immune response. Virology 333:263-70. 
20. Brandt, T. A., and B. L. Jacobs. 2001. Both carboxy- and amino-
terminal domains of the vaccinia virus interferon resistance gene, E3L, are 
required for pathogenesis in a mouse model. J Virol 75:850-6. 
21. Breman, J. G. 2000. Monkeypox:  an Emerging Infection Humans? 
22. Breman, J. G., and I. Arita. 1980. The confirmation and maintenance of 
smallpox eradication. N Engl J Med 303:1263-73. 
23. Buller, R. M., and G. J. Palumbo. 1991. Poxvirus pathogenesis. 
Microbiol Rev 55:80-122. 
24. Cameron, C., S. Hota-Mitchell, L. Chen, J. Barrett, J. X. Cao, C. 
Macaulay, D. Willer, D. Evans, and G. McFadden. 1999. The complete 
DNA sequence of myxoma virus. Virology 264:298-318. 
25. Cantley, L. C., K. R. Auger, C. Carpenter, B. Duckworth, A. 
Graziani, R. Kapeller, and S. Soltoff. 1991. Oncogenes and signal 
transduction. Cell 64:281-302. 
26. Carroll, K., O. Elroy-Stein, B. Moss, and R. Jagus. 1993. Recombinant 
vaccinia virus K3L gene product prevents activation of double-stranded 
RNA-dependent, initiation factor 2 alpha-specific protein kinase. J Biol 
Chem 268:12837-42. 
27. Cascallo, M., G. Capella, A. Mazo, and R. Alemany. 2003. Ras-
dependent oncolysis with an adenovirus VAI mutant. Cancer Res 
63:5544-50. 
28. Chang, H. W., and B. L. Jacobs. 1993. Identification of a conserved 
motif that is necessary for binding of the vaccinia virus E3L gene products 
to double-stranded RNA. Virology 194:537-47. 
29. Chang, H. W., L. H. Uribe, and B. L. Jacobs. 1995. Rescue of vaccinia 
virus lacking the E3L gene by mutants of E3L. J Virol 69:6605-8. 
  136 
30. Chang, H. W., J. C. Watson, and B. L. Jacobs. 1992. The E3L gene of 
vaccinia virus encodes an inhibitor of the interferon-induced, double-
stranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A 
89:4825-9. 
31. Chawla-Sarkar, M., D. J. Lindner, Y. F. Liu, B. R. Williams, G. C. 
Sen, R. H. Silverman, and E. C. Borden. 2003. Apoptosis and 
interferons: role of interferon-stimulated genes as mediators of apoptosis. 
Apoptosis 8:237-49. 
32. Chen, N., G. Li, M. K. Liszewski, J. P. Atkinson, P. B. Jahrling, Z. 
Feng, J. Schriewer, C. Buck, C. Wang, E. J. Lefkowitz, J. J. Esposito, 
T. Harms, I. K. Damon, R. L. Roper, C. Upton, and R. M. Buller. 
2005. Virulence differences between monkeypox virus isolates from West 
Africa and the Congo basin. Virology 340:46-63. 
33. Coffey, M. C., J. E. Strong, P. A. Forsyth, and P. W. Lee. 1998. 
Reovirus therapy of tumors with activated Ras pathway. Science 
282:1332-4. 
34. Cohrs, R. J., R. C. Condit, R. F. Pacha, C. L. Thompson, and O. K. 
Sharma. 1989. Modulation of ppp(A2'p)nA-dependent RNase by a 
temperature-sensitive mutant of vaccinia virus. J Virol 63:948-51. 
35. Condit, R. C., and E. G. Niles. 2002. Regulation of viral transcription 
elongation and termination during vaccinia virus infection. Biochim 
Biophys Acta 1577:325-36. 
36. Cooper, J. A., B. Moss, and E. Katz. 1979. Inhibition of vaccinia virus 
late protein synthesis by isatin-beta-thiosemicarbazone: characterization 
and in vitro translation of viral mRNA. Virology 96:381-92. 
37. Cresawn, S. G., and R. C. Condit. 2007. A targeted approach to 
identification of vaccinia virus postreplicative transcription elongation 
factors: genetic evidence for a role of the H5R gene in vaccinia 
transcription. Virology 363:333-41. 
38. Cresawn, S. G., C. Prins, D. R. Latner, and R. C. Condit. 2007. 
Mapping and phenotypic analysis of spontaneous isatin-beta-
  137 
thiosemicarbazone resistant mutants of vaccinia virus. Virology 363:319-
32. 
39. Cross, J. C., S. Lam, S. Yagel, and Z. Werb. 1999. Defective induction 
of the transcription factor interferon-stimulated gene factor-3 and 
interferon alpha insensitivity in human trophoblast cells. Biol Reprod 
60:312-21. 
40. Cuddihy, A. R., S. Li, N. W. Tam, A. H. Wong, Y. Taya, N. Abraham, 
J. C. Bell, and A. E. Koromilas. 1999. Double-stranded-RNA-activated 
protein kinase PKR enhances transcriptional activation by tumor 
suppressor p53. Mol Cell Biol 19:2475-84. 
41. de Veer, M. J., M. Holko, M. Frevel, E. Walker, S. Der, J. M. 
Paranjape, R. H. Silverman, and B. R. Williams. 2001. Functional 
classification of interferon-stimulated genes identified using microarrays. J 
Leukoc Biol 69:912-20. 
42. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. 
Identification of genes differentially regulated by interferon alpha, beta, or 
gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95:15623-
8. 
43. Dunn, G. P., A. T. Bruce, K. C. Sheehan, V. Shankaran, R. Uppaluri, 
J. D. Bui, M. S. Diamond, C. M. Koebel, C. Arthur, J. M. White, and 
R. D. Schreiber. 2005. A critical function for type I interferons in cancer 
immunoediting. Nat Immunol 6:722-9. 
44. Easterbrook, K. B. 1962. Interference with the maturation of vaccinia 
virus by isatin beta-thiosemicarbazone. Virology 17:245-51. 
45. Farassati, F., A. D. Yang, and P. W. Lee. 2001. Oncogenes in Ras 
signalling pathway dictate host-cell permissiveness to herpes simplex 
virus 1. Nat Cell Biol 3:745-50. 
46. Fine, P. E., Z. Jezek, B. Grab, and H. Dixon. 1988. The transmission 
potential of monkeypox virus in human populations. Int J Epidemiol 
17:643-50. 
  138 
47. Floyd-Smith, G., E. Slattery, and P. Lengyel. 1981. Interferon action: 
RNA cleavage pattern of a (2'-5')oligoadenylate--dependent endonuclease. 
Science 212:1030-2. 
48. Grimley, P. M., H. Fang, H. Rui, E. F. Petricoin, 3rd, S. Ray, F. Dong, 
K. H. Fields, R. Hu, K. C. Zoon, S. Audet, and J. Beeler. 1998. 
Prolonged STAT1 activation related to the growth arrest of malignant 
lymphoma cells by interferon-alpha. Blood 91:3017-27. 
49. Guha, A., M. M. Feldkamp, N. Lau, G. Boss, and A. Pawson. 1997. 
Proliferation of human malignant astrocytomas is dependent on Ras 
activation. Oncogene 15:2755-65. 
50. Herbert, A., J. Alfken, Y. G. Kim, I. S. Mian, K. Nishikura, and A. 
Rich. 1997. A Z-DNA binding domain present in the human editing 
enzyme, double-stranded RNA adenosine deaminase. Proc Natl Acad Sci 
U S A 94:8421-6. 
51. Ho, C. K., and S. Shuman. 1996. Mutational analysis of the vaccinia 
virus E3 protein defines amino acid residues involved in E3 binding to 
double-stranded RNA. J Virol 70:2611-4. 
52. Ho, C. K., and S. Shuman. 1996. Physical and functional 
characterization of the double-stranded RNA binding protein encoded by 
the vaccinia virus E3 gene. Virology 217:272-84. 
53. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. 
Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. 
IRF-7 is the master regulator of type-I interferon-dependent immune 
responses. Nature 434:772-7. 
54. Huhn, G. D., A. M. Bauer, K. Yorita, M. B. Graham, J. Sejvar, A. 
Likos, I. K. Damon, M. G. Reynolds, and M. J. Kuehnert. 2005. 
Clinical characteristics of human monkeypox, and risk factors for severe 
disease. Clin Infect Dis 41:1742-51. 
55. Ichihashi, Y. 1996. Extracellular enveloped vaccinia virus escapes 
neutralization. Virology 217:478-85. 
  139 
56. Isaacs, S. N., G. J. Kotwal, and B. Moss. 1992. Vaccinia virus 
complement-control protein prevents antibody-dependent complement-
enhanced neutralization of infectivity and contributes to virulence. Proc 
Natl Acad Sci U S A 89:628-32. 
57. Jacobs, B. L., and J. O. Langland. 1996. When two strands are better 
than one: the mediators and modulators of the cellular responses to 
double-stranded RNA. Virology 219:339-49. 
58. Kato, H., S. Sato, M. Yoneyama, M. Yamamoto, S. Uematsu, K. 
Matsui, T. Tsujimura, K. Takeda, T. Fujita, O. Takeuchi, and S. 
Akira. 2005. Cell type-specific involvement of RIG-I in antiviral 
response. Immunity 23:19-28. 
59. Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. 
Matsui, S. Uematsu, A. Jung, T. Kawai, K. J. Ishii, O. Yamaguchi, K. 
Otsu, T. Tsujimura, C. S. Koh, C. Reis e Sousa, Y. Matsuura, T. 
Fujita, and S. Akira. 2006. Differential roles of MDA5 and RIG-I 
helicases in the recognition of RNA viruses. Nature 441:101-5. 
60. Katz, E., E. Margalith, B. Winer, and N. Goldblum. 1973. Synthesis of 
vaccinia virus polypeptides in the presence of isatin-beta-
thiosemicarbazone. Antimicrob Agents Chemother 4:44-8. 
61. Kawai, T., K. Takahashi, S. Sato, C. Coban, H. Kumar, H. Kato, K. J. 
Ishii, O. Takeuchi, and S. Akira. 2005. IPS-1, an adaptor triggering 
RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 
6:981-8. 
62. Keck, J. G., C. J. Baldick, Jr., and B. Moss. 1990. Role of DNA 
replication in vaccinia virus gene expression: a naked template is required 
for transcription of three late trans-activator genes. Cell 61:801-9. 
63. Kerr, I. M., R. E. Brown, and A. G. Hovanessian. 1977. Nature of 
inhibitor of cell-free protein synthesis formed in response to interferon and 
double-stranded RNA. Nature 268:540-2. 
64. Khodakevich, L., Z. Jezek, and D. Messinger. 1988. Monkeypox virus: 
ecology and public health significance. Bull World Health Organ 66:747-
52. 
  140 
65. Kibler, K. V., T. Shors, K. B. Perkins, C. C. Zeman, M. P. Banaszak, 
J. Biesterfeldt, J. O. Langland, and B. L. Jacobs. 1997. Double-
stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J 
Virol 71:1992-2003. 
66. Kim, Y. G., K. Lowenhaupt, D. B. Oh, K. K. Kim, and A. Rich. 2004. 
Evidence that vaccinia virulence factor E3L binds to Z-DNA in vivo: 
Implications for development of a therapy for poxvirus infection. Proc 
Natl Acad Sci U S A 101:1514-8. 
67. Kim, Y. G., M. Muralinath, T. Brandt, M. Pearcy, K. Hauns, K. 
Lowenhaupt, B. L. Jacobs, and A. Rich. 2003. A role for Z-DNA 
binding in vaccinia virus pathogenesis. Proc Natl Acad Sci U S A 
100:6974-9. 
68. Kirn, D. H., and S. H. Thorne. 2009. Targeted and armed oncolytic 
poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat 
Rev Cancer 9:64-71. 
69. Kirn, D. H., Y. Wang, W. Liang, C. H. Contag, and S. H. Thorne. 
2008. Enhancing poxvirus oncolytic effects through increased spread and 
immune evasion. Cancer Res 68:2071-5. 
70. Kotwal, G. J., S. N. Isaacs, R. McKenzie, M. M. Frank, and B. Moss. 
1990. Inhibition of the complement cascade by the major secretory protein 
of vaccinia virus. Science 250:827-30. 
71. Kotwal, G. J., and B. Moss. 1988. Vaccinia virus encodes a secretory 
polypeptide structurally related to complement control proteins. Nature 
335:176-8. 
72. Koyama, S., K. J. Ishii, C. Coban, and S. Akira. 2008. Innate immune 
response to viral infection. Cytokine 43:336-41. 
73. Krishnamoorthy, T., G. D. Pavitt, F. Zhang, T. E. Dever, and A. G. 
Hinnebusch. 2001. Tight binding of the phosphorylated alpha subunit of 
initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine 
nucleotide exchange factor eIF2B is required for inhibition of translation 
initiation. Mol Cell Biol 21:5018-30. 
  141 
74. Krug, A., G. D. Luker, W. Barchet, D. A. Leib, S. Akira, and M. 
Colonna. 2004. Herpes simplex virus type 1 activates murine natural 
interferon-producing cells through toll-like receptor 9. Blood 103:1433-7. 
75. Langland, J. O., and B. L. Jacobs. 2004. Inhibition of PKR by vaccinia 
virus: role of the N- and C-terminal domains of E3L. Virology 324:419-
29. 
76. Langland, J. O., and B. L. Jacobs. 2002. The role of the PKR-inhibitory 
genes, E3L and K3L, in determining vaccinia virus host range. Virology 
299:133-41. 
77. Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki. 2003. Toll-
like receptor 9-mediated recognition of Herpes simplex virus-2 by 
plasmacytoid dendritic cells. J Exp Med 198:513-20. 
78. Malathi, K., B. Dong, M. Gale, Jr., and R. H. Silverman. 2007. Small 
self-RNA generated by RNase L amplifies antiviral innate immunity. 
Nature 448:816-9. 
79. Marennikova, S. S., E. M. Seluhina, N. N. Mal'ceva, K. L. Cimiskjan, 
and G. R. Macevic. 1972. Isolation and properties of the causal agent of a 
new variola-like disease (monkeypox) in man. Bull World Health Organ 
46:599-611. 
80. Matin, S. F., R. R. Rackley, P. C. Sadhukhan, M. S. Kim, A. C. 
Novick, and S. K. Bandyopadhyay. 2001. Impaired alpha-interferon 
signaling in transitional cell carcinoma: lack of p48 expression in 5637 
cells. Cancer Res 61:2261-6. 
81. McCartney, S. A., and M. Colonna. 2009. Viral sensors: diversity in 
pathogen recognition. Immunol Rev 227:87-94. 
82. McCormick, F. 1993. Signal transduction. How receptors turn Ras on. 
Nature 363:15-6. 
83. McIntosh, A. A., and G. L. Smith. 1996. Vaccinia virus glycoprotein 
A34R is required for infectivity of extracellular enveloped virus. J Virol 
70:272-81. 
  142 
84. Meurs, E., K. Chong, J. Galabru, N. S. Thomas, I. M. Kerr, B. R. 
Williams, and A. G. Hovanessian. 1990. Molecular cloning and 
characterization of the human double-stranded RNA-activated protein 
kinase induced by interferon. Cell 62:379-90. 
85. Meylan, E., J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. 
Bartenschlager, and J. Tschopp. 2005. Cardif is an adaptor protein in 
the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 
437:1167-72. 
86. Moss, B. 1990. Regulation of vaccinia virus transcription. Annu Rev 
Biochem 59:661-88. 
87. Moss, B., and J. L. Shisler. 2001. Immunology 101 at poxvirus U: 
immune evasion genes. Semin Immunol 13:59-66. 
88. Mundschau, L. J., and D. V. Faller. 1994. Endogenous inhibitors of the 
dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-
transformed cells. Biochimie 76:792-800. 
89. Norman, K. L., M. C. Coffey, K. Hirasawa, D. J. Demetrick, S. G. 
Nishikawa, L. M. DiFrancesco, J. E. Strong, and P. W. Lee. 2002. 
Reovirus oncolysis of human breast cancer. Hum Gene Ther 13:641-52. 
90. Pansky, A., P. Hildebrand, E. Fasler-Kan, L. Baselgia, S. Ketterer, C. 
Beglinger, and M. H. Heim. 2000. Defective Jak-STAT signal 
transduction pathway in melanoma cells resistant to growth inhibition by 
interferon-alpha. Int J Cancer 85:720-5. 
91. Parato, K. A., D. Senger, P. A. Forsyth, and J. C. Bell. 2005. Recent 
progress in the battle between oncolytic viruses and tumours. Nat Rev 
Cancer 5:965-76. 
92. Parker, S., A. Nuara, R. M. Buller, and D. A. Schultz. 2007. Human 
monkeypox: an emerging zoonotic disease. Future Microbiol 2:17-34. 
93. Patterson, J. B., and C. E. Samuel. 1995. Expression and regulation by 
interferon of a double-stranded-RNA-specific adenosine deaminase from 
  143 
human cells: evidence for two forms of the deaminase. Mol Cell Biol 
15:5376-88. 
94. Pennington, T. H. 1977. Isatin-beta-thiosemicarbazone causes premature 
cessation of vaccinia virus-induced late post-replicative polypeptide 
synthesis. J Gen Virol 35:567-71. 
95. Perdiguero, B., and M. Esteban. 2009. The interferon system and 
vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29:581-98. 
96. Pichlmair, A., O. Schulz, C. P. Tan, T. I. Naslund, P. Liljestrom, F. 
Weber, and C. Reis e Sousa. 2006. RIG-I-mediated antiviral responses to 
single-stranded RNA bearing 5'-phosphates. Science 314:997-1001. 
97. Prins, C., S. G. Cresawn, and R. C. Condit. 2004. An isatin-beta-
thiosemicarbazone-resistant vaccinia virus containing a mutation in the 
second largest subunit of the viral RNA polymerase is defective in 
transcription elongation. J Biol Chem 279:44858-71. 
98. Randall, R. E., and S. Goodbourn. 2008. Interferons and viruses: an 
interplay between induction, signalling, antiviral responses and virus 
countermeasures. J Gen Virol 89:1-47. 
99. Rebouillat, D., and A. G. Hovanessian. 1999. The human 2',5'-
oligoadenylate synthetase family: interferon-induced proteins with unique 
enzymatic properties. J Interferon Cytokine Res 19:295-308. 
100. Reed, K. D., J. W. Melski, M. B. Graham, R. L. Regnery, M. J. Sotir, 
M. V. Wegner, J. J. Kazmierczak, E. J. Stratman, Y. Li, J. A. Fairley, 
G. R. Swain, V. A. Olson, E. K. Sargent, S. C. Kehl, M. A. Frace, R. 
Kline, S. L. Foldy, J. P. Davis, and I. K. Damon. 2004. The detection of 
monkeypox in humans in the Western Hemisphere. N Engl J Med 
350:342-50. 
101. Romano, P. R., F. Zhang, S. L. Tan, M. T. Garcia-Barrio, M. G. 
Katze, T. E. Dever, and A. G. Hinnebusch. 1998. Inhibition of double-
stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of 
complex formation and the E3 N-terminal domain. Mol Cell Biol 
18:7304-16. 
  144 
102. Russell, S. J. 2002. RNA viruses as virotherapy agents. Cancer Gene Ther 
9:961-6. 
103. Sadler, A. J., and B. R. Williams. 2008. Interferon-inducible antiviral 
effectors. Nat Rev Immunol 8:559-68. 
104. Samuel, C. E. 2001. Antiviral actions of interferons. Clin Microbiol Rev 
14:778-809, table of contents. 
105. Sangfelt, and H. Strander. 2001. Apoptosis and cell growth inhibition as 
antitumor effector functions of interferons. Med Oncol 18:3-14. 
106. Savinova, O., B. Joshi, and R. Jagus. 1999. Abnormal levels and 
minimal activity of the dsRNA-activated protein kinase, PKR, in breast 
carcinoma cells. The International Journal of Biochemistry and Cell 
Biology 31:175-189. 
107. Schonborn, J., J. Oberstrass, E. Breyel, J. Tittgen, J. Schumacher, 
and N. Lukacs. 1991. Monoclonal antibodies to double-stranded RNA as 
probes of RNA structure in crude nucleic acid extracts. Nucleic Acids Res 
19:2993-3000. 
108. Schwartz, T., M. A. Rould, K. Lowenhaupt, A. Herbert, and A. Rich. 
1999. Crystal structure of the Zalpha domain of the human editing enzyme 
ADAR1 bound to left-handed Z-DNA. Science 284:1841-5. 
109. Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, 
C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 
2003. Poxviruses and immune evasion. Annu Rev Immunol 21:377-423. 
110. Sen, G. C. 2000. Novel functions of interferon-induced proteins. Semin 
Cancer Biol 10:93-101. 
111. Seth, R. B., L. Sun, C. K. Ea, and Z. J. Chen. 2005. Identification and 
characterization of MAVS, a mitochondrial antiviral signaling protein that 
activates NF-kappaB and IRF 3. Cell 122:669-82. 
  145 
112. Sharp, T. V., F. Moonan, A. Romashko, B. Joshi, G. N. Barber, and R. 
Jagus. 1998. The vaccinia virus E3L gene product interacts with both the 
regulatory and the substrate binding regions of PKR: implications for PKR 
autoregulation. Virology 250:302-15. 
113. Shors, S. T., E. Beattie, E. Paoletti, J. Tartaglia, and B. L. Jacobs. 
1998. Role of the vaccinia virus E3L and K3L gene products in rescue of 
VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res 
18:721-9. 
114. Shors, T., K. V. Kibler, K. B. Perkins, R. Seidler-Wulff, M. P. 
Banaszak, and B. L. Jacobs. 1997. Complementation of vaccinia virus 
deleted of the E3L gene by mutants of E3L. Virology 239:269-76. 
115. Silverman, R. H. 2003. Implications for RNase L in prostate cancer 
biology. Biochemistry 42:1805-12. 
116. Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplasschen, and A. 
Alcami. 1997. Vaccinia virus immune evasion. Immunol Rev 159:137-54. 
117. Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation 
and function of extracellular enveloped vaccinia virus. J Gen Virol 
83:2915-31. 
118. Smith, M. R., S. J. DeGudicibus, and D. W. Stacey. 1986. Requirement 
for c-ras proteins during viral oncogene transformation. Nature 320:540-3. 
119. Smith, V. P., N. A. Bryant, and A. Alcami. 2000. Ectromelia, vaccinia 
and cowpox viruses encode secreted interleukin-18-binding proteins. J 
Gen Virol 81:1223-30. 
120. St Johnston, D., N. H. Brown, J. G. Gall, and M. Jantsch. 1992. A 
conserved double-stranded RNA-binding domain. Proc Natl Acad Sci U S 
A 89:10979-83. 
121. Stanford, M. M., G. McFadden, G. Karupiah, and G. Chaudhri. 2007. 
Immunopathogenesis of poxvirus infections: forecasting the impending 
storm. Immunol Cell Biol 85:93-102. 
  146 
122. Stojdl, D. F., B. Lichty, S. Knowles, R. Marius, H. Atkins, N. 
Sonenberg, and J. C. Bell. 2000. Exploiting tumor-specific defects in the 
interferon pathway with a previously unknown oncolytic virus. Nat Med 
6:821-5. 
123. Stojdl, D. F., B. D. Lichty, B. R. tenOever, J. M. Paterson, A. T. 
Power, S. Knowles, R. Marius, J. Reynard, L. Poliquin, H. Atkins, E. 
G. Brown, R. K. Durbin, J. E. Durbin, J. Hiscott, and J. C. Bell. 2003. 
VSV strains with defects in their ability to shutdown innate immunity are 
potent systemic anti-cancer agents. Cancer Cell 4:263-75. 
124. Strong, J. E., M. C. Coffey, D. Tang, P. Sabinin, and P. W. Lee. 1998. 
The molecular basis of viral oncolysis: usurpation of the Ras signaling 
pathway by reovirus. EMBO J 17:3351-62. 
125. Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus 
encodes a soluble type I interferon receptor of novel structure and broad 
species specificity. Cell 81:551-60. 
126. Takahashi, K., T. Kawai, H. Kumar, S. Sato, S. Yonehara, and S. 
Akira. 2006. Roles of caspase-8 and caspase-10 in innate immune 
responses to double-stranded RNA. J Immunol 176:4520-4. 
127. Takahasi, K., M. Yoneyama, T. Nishihori, R. Hirai, H. Kumeta, R. 
Narita, M. Gale, Jr., F. Inagaki, and T. Fujita. 2008. Nonself RNA-
sensing mechanism of RIG-I helicase and activation of antiviral immune 
responses. Mol Cell 29:428-40. 
128. Takaoka, A., and H. Yanai. 2006. Interferon signalling network in innate 
defence. Cell Microbiol 8:907-22. 
129. Takeuchi, O., and S. Akira. 2007. Recognition of viruses by innate 
immunity. Immunol Rev 220:214-24. 
130. Thorne, S. H., D. L. Bartlett, and D. H. Kirn. 2005. The use of 
oncolytic vaccinia viruses in the treatment of cancer: a new role for an old 
ally? Curr Gene Ther 5:429-43. 
  147 
131. Tuzi, N. L., D. J. Venter, S. Kumar, S. L. Staddon, N. R. Lemoine, and 
W. J. Gullick. 1991. Expression of growth factor receptors in human 
brain tumours. Br J Cancer 63:227-33. 
132. Ueda, T., Y. Gotoh, K. Shiroshita, T. Sakurai, and Y. Kataoka. 1990. 
[Clinical and histological observation of HBV glomerulonephritis treated 
with interferon-beta]. Nippon Jinzo Gakkai Shi 32:1153-9. 
133. Upton, C., S. Slack, A. L. Hunter, A. Ehlers, and R. L. Roper. 2003. 
Poxvirus orthologous clusters: toward defining the minimum essential 
poxvirus genome. J Virol 77:7590-600. 
134. Varghese, S., and S. D. Rabkin. 2002. Oncolytic herpes simplex virus 
vectors for cancer virotherapy. Cancer Gene Ther 9:967-78. 
135. Verardi, P. H., L. A. Jones, F. H. Aziz, S. Ahmad, and T. D. Yilma. 
2001. Vaccinia virus vectors with an inactivated gamma interferon 
receptor homolog gene (B8R) are attenuated In vivo without a 
concomitant reduction in immunogenicity. J Virol 75:11-8. 
136. Vijaysri, S., G. Jentarra, M. C. Heck, A. A. Mercer, C. J. McInnes, 
and B. L. Jacobs. 2008. Vaccinia viruses with mutations in the E3L gene 
as potential replication-competent, attenuated vaccines: intra-nasal 
vaccination. Vaccine 26:664-76. 
137. Watson, J. C., H. W. Chang, and B. L. Jacobs. 1991. Characterization 
of a vaccinia virus-encoded double-stranded RNA-binding protein that 
may be involved in inhibition of the double-stranded RNA-dependent 
protein kinase. Virology 185:206-16. 
138. Wong, L. H., K. G. Krauer, I. Hatzinisiriou, M. J. Estcourt, P. Hersey, 
N. D. Tam, S. Edmondson, R. J. Devenish, and S. J. Ralph. 1997. 
Interferon-resistant human melanoma cells are deficient in ISGF3 
components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 
272:28779-85. 
139. Woodson, B., and W. K. Joklik. 1965. The inhibition of vaccinia virus 
multiplication by isatin-beta-thiosemicarbazone. Proc Natl Acad Sci U S 
A 54:946-53. 
  148 
140. Wright, C. F., J. G. Keck, M. M. Tsai, and B. Moss. 1991. A 
transcription factor for expression of vaccinia virus late genes is encoded 
by an intermediate gene. J Virol 65:3715-20. 
141. Wright, C. F., and B. Moss. 1989. Identification of factors specific for 
transcription of the late class of vaccinia virus genes. J Virol 63:4224-33. 
142. Xu, L. G., Y. Y. Wang, K. J. Han, L. Y. Li, Z. Zhai, and H. B. Shu. 
2005. VISA is an adapter protein required for virus-triggered IFN-beta 
signaling. Mol Cell 19:727-40. 
143. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. 
Takeda, and S. Akira. 2002. Cutting edge: a novel Toll/IL-1 receptor 
domain-containing adapter that preferentially activates the IFN-beta 
promoter in the Toll-like receptor signaling. J Immunol 169:6668-72. 
144. Yuwen, H., J. H. Cox, J. W. Yewdell, J. R. Bennink, and B. Moss. 
1993. Nuclear localization of a double-stranded RNA-binding protein 
encoded by the vaccinia virus E3L gene. Virology 195:732-44. 
145. Zhou, A., B. A. Hassel, and R. H. Silverman. 1993. Expression cloning 
of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon 
action. Cell 72:753-65. 
 
  
